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Abstract 
This collection of papers aims to addresses why, and how, uncertainty should be 
incorporated within economic evaluations of health care technologies and how the results 
can be used to inform decision making.  Section one provides a brief overview of the 
methodological and policy background of using economic evaluation to inform decisions 
about health care technologies.  With the context for utilising economic evaluation to 
inform reimbursement decisions established, sources of uncertainty are considered at each 
stage of the evaluation.  Section two discusses the identification of relevant evidence to 
inform estimates of the effectiveness of health care technologies.  The key uncertainty 
addressed is how to assess whether the available evidence can be analysed to provide an 
unbiased estimate of the treatment effect.  As multiple sources of evidence may exist, 
Section three explains how they can be combined to sum up the available evidence, and in 
Section four the techniques for characterising uncertainty within that combined analysis are 
examined.  Sections five and six demonstrate why a characterisation of uncertainty is 
crucial in order to inform decisions about the need for further research and the 
consequences of making reimbursement decisions under uncertainty.  Methods to establish 
the opportunity cost of uncertainty and sufficiency of the evidence base are reviewed in 
Section five with a view to informing decisions to acquire further research.  In Section six 
the irreversible aspects of reimbursement decisions, as well as the interdependence of 
decisions about reimbursement and about further research is illustrated.  These factors 
spell out why an economic evaluation that does not deal with uncertainty will be 
inadequate for informing reimbursement decisions.  Finally, Section seven concludes the 
thesis and summarises the contribution of the presented papers and areas for further 
research. 
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1. Methods and policy background 
Within the health care sector there exist numerous competing health care interventions 
and programmes, of which only a proportion can be provided with the resources available.  
The challenge is in identifying which interventions to provide given the resource 
constraints, and this can be informed by an assessment of the costs and benefits 
attributable to each intervention.6 7  Decisions about allocating collective resources need to 
be made in a justifiable and auditable manner, so any methods need to make explicit the 
underlying scientific and social value judgements.  Those judgements, amongst other things, 
determine which costs are considered relevant, what are the benefits and how should they 
be measured and the limits of the available resources.  The benefits of health care 
interventions can be measured in terms of the amount of health they generate.  The use of 
health as the outcome of interest when evaluating returns from investments would seem 
consistent with the aim of providing collectively funded health care8 9 but represents a 
departure from neoclassical economics in which benefits would always be measured in 
terms of individuals’ subjective utilities.10 However, this departure is necessary if it is not 
considered possible to appropriately value health outcomes in the same way as benefits 
derived from the consumption of goods and services.11 For the resource constraint to be 
endogenous some knowledge of the social welfare function is required in order to value 
health care relative to other activities.12 13  However, if one accepts the existence of a 
legitimate social process for determining the budget allocated to health care, the relevant 
resources can be regarded as fixed and determined exogenously.14 With this value 
judgement the allocation problem takes the form of a constrained optimisation to maximise 
health gains subject to a budget constraint, and the relevant costs are those that fall on the 
budget constraint.  The most cost-effective use of available resources would be the one 
that provides the greatest health benefits. 
 
The costs and health outcomes of interventions can be estimated by referring to available 
evidence that describe the course of the disease, health outcomes and health service 
resource use by individuals who receive them.  By identifying all possible interventions for 
all potential recipients, calculating for each the expected health outcomes and cost burden 
and comparing this to the total amount of resources available, it would be possible to solve 
the whole allocation problem simultaneously using mathematical programming 
techniques.15-17  However, the informational requirements of this global approach make it 
impractical.  To make the problem manageable it may be necessary to consider the choice 
between all relevant treatment options for a specific indication.  Should one of the mutually 
exclusive options be found to offer an improvement in health gains but at a greater cost 
than the currently funded alternative, the potential health outcomes must be compared to 
those lost from interventions displaced by reallocating resources to fund the new 
intervention.18 19  Identifying and evaluating targets for disinvestment may be difficult in 
practice,20 and instead an estimation of the shadow price of the budget constraint may 
provide a threshold for assessing cost-effectiveness.21  
 
These comparisons necessitate the use of a summary index measure of health outcomes 
that is common across all interventions in all disease areas.  In practice this is often 
estimated by weighting survival according to some preference-based measure of health-
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related quality of life (HRQL) to generate quality adjusted life years (QALYs).22-24  The 
evidence and methods of calculation must distinguish the health gains that are attributable 
to the use of different interventions.  In practice the process of identifying the available 
evidence and the manner in which it is interpreted and used to calculate expected costs 
and health outcomes will be subject to uncertainty.  Uncertainty in estimates of cost-
effectiveness leads to the possibility that the wrong set of interventions is funded such that 
population health is not maximised, and hence there is an opportunity cost to uncertainty 
in terms of health forgone.  The uncertainty in evidence can be characterised by describing 
the range and likelihood of alternative plausible values and assumptions supported by the 
evidence, and from this computing a distribution of costs and health outcomes for each 
treatment under evaluation.  Using this distribution it is possible to address questions about 
whether the current evidence base is sufficient to support the choice between alternative 
treatments and whether further research is valuable.  Methods for calculating the value of 
eliminating decision uncertainty are well-established.25-27  This provides an upper bound for 
the value of additional research to reduce that uncertainty, which can be compared to the 
costs of conducting that research.28  On the basis of the available evidence, the decision 
maker can maximize expected health by reimbursing the treatments with the highest 
expected net benefits.  There may be an error probability associated with those decisions, 
but any other allocation of resources would be associated with a lower expected level of 
health. However, reducing the likelihood of wrong decisions would also increase the 
expected level of health.29 30 This can be achieved by acquiring more evidence, whether 
actively or passively, to reduce the decision uncertainty.  When accounting for uncertainty 
the costs of reversing decisions in light of new evidence should be incorporated in the 
analysis.31  While population health benefits can be maximised by optimising reimbursement 
decisions to fund interventions and to fund further research, those two actions are not 
mutually independent.5 
 
The value of economic evaluation in supporting reimbursement decisions is evidenced by 
the proliferation of national institutions with the remit to grant approval for the use of 
particular health interventions within health services worldwide on the basis of a review of 
available evidence and an assessment of cost-effectiveness.32 33  Thus advancing the methods 
for economic evaluation can have a direct impact on uncertain decisions about resource 
allocation in health care systems around the world.   
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2. Identifying evidence of treatment effects 
To identify from the wealth of available information the sources of evidence on which a 
particular assessment of cost-effectiveness should be based, it is necessary to specify 
criteria for determining the relevance of evidence.  Estimation of treatment effects, that is 
the change in health outcomes or resource use that would result from the use of an 
intervention, requires evidence on the causal effects of interventions.34  The desired 
information is what the health outcomes and resource use would be with the intervention 
and what would have happened without the intervention.  However, it is impossible 
directly to observe the counterfactual as, at any given point in time, we can only observe an 
individual either with or without the intervention, and must also rely on past observations 
to predict the experiences of future patients.  Thus the relevance of any source of evidence 
for estimating a treatment effect depends on its ability to approximate the counterfactual in 
the studied population and how generalisable are the estimates of treatment effect to the 
target population.34  The ability to identify a causal relationship between interventions and 
outcomes (by approximating the counterfactual) is often referred to as internal validity.35  
The extent to which the results in the studied population hold true for the target 
population is often referred to as external validity.36  An estimate that lacks validity can be 
described as biased because it differs systematically from the true value it is intended to 
describe.  Unbiased estimates will be uncertain due to sampling error (unless the full 
population is observed), and any bias is an additional source of uncertainty in its extent and 
magnitude.  If the internal or external validity of a source of evidence is judged to be too 
low it could be said to be irrelevant to the decision problem. 
 
2.1 Impact of method of data collection on potential for bias 
Randomised controlled trials (RCTs) are designed to minimise bias in identifying the causal 
effects of interventions.  They do this by allocating patients to different interventions in a 
way that guarantees no systematic differences in the baseline characteristics of individuals 
within the treated and control groups.37  This allows average treatment effects to be 
estimated by a simple comparison of the mean outcome in each group.  Treatment effects 
calculated in this way have high internal validity as they describe with minimum bias the 
effects on the outcome in the study participants.  However the rigours of designing such a 
study to enable the detection of a clear treatment effect (signal) can be restrictive.  The 
units of observation (e.g. patients), the treatments provided, the observations made on the 
units and the setting in which the study is conducted may differ to those pertaining to the 
decision problem that the study seeks to inform, leading to problems with generalisability.38  
For example, strict inclusion and exclusion criteria may mean that the patients recruited 
differ systematically in their characteristics compared to the wider population or the 
individual patient for whom treatment is intended.39 40  The restrictive nature of 
randomised trials means that for some interventions or patient populations of interest, it is 
not feasible to design a randomised trial due to reasons of practicality, cost or ethics.41  In 
these circumstances an alternative source of evidence are quasi-experimental studies in 
which treatment is not assigned by randomisation.35  However, when assignment to 
treatment selected, whether by patients, doctors or researchers, or when randomisation is 
unsuccessful, a simple unadjusted comparison of outcomes between treatment groups 
would be subject to selection bias.  This is due to confounding by patient characteristics 
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that determine both whether a patient would receive an intervention and their post-
intervention costs and health gains. 
 
2.2. Methods of analysis to control for selection bias 
There exists a range of methods to recover unbiased estimates of treatment effects from 
non-randomised studies by controlling for potential confounding.  Where treatment 
assignment is determined by characteristics of individuals observed by the analyst (selection 
on observables), then regression analysis and methods of matching, including propensity 
scores, can be utilised.42  In a regression framework it might be sufficient to condition on 
the set of confounding characteristics when estimating the relationship between the 
intervention and outcomes of interest. If the specification of the model conforms to the 
underlying data generating process this will produce an unbiased estimate of the treatment 
effect.  An alternative method that does not rely on the parametric assumptions 
underpinning the regression approach is the method of matching.43  The outcomes of 
treated individuals are compared to a matched comparison group for whom observed pre-
treatment characteristics match those of the treated group up to some chosen degree of 
proximity.  If suitably matched individuals can be identified, then their average outcomes 
provide the counterfactual for the average outcome for treated individuals.  A number of 
methods have been proposed for defining a suitably matched group of individuals and a 
leading method is propensity score matching.44  Where selection into treatment is based 
on unobservable characteristics of individuals, regression analysis is unsuitable and the 
method of instrumental variables (IV) can theoretically be used to make inference about 
the causal effect of an intervention.45 An instrument is a covariate that is correlated with 
treatment assignment but is not independently correlated with outcome (i.e. other than 
through its influence on treatment assignment).  Randomisation is therefore the perfect 
instrument, and a suitable instrumental variable is one that operates by the same 
mechanism.  By utilising independent information in the instrument to determine treatment 
assignment, the method seeks to infer the underlying treatment effect.  However, in 
practice it is difficult to find a suitable instrument and so examples of economic analyses 
that utilise IV are rare.  Another approach is to model the selection mechanism directly.  
That is, if the characteristic determining selection was not observed, it may be possible to 
specify a model to predict its value in order to incorporate it within subsequent analyses to 
control for sample selection bias.46 
 
2.3 Methods to correct for missing outcomes and data 
The choice of outcome measures can be determined at the design stage for an RCT, but 
quasi-experimental studies conducted in ‘naturalistic settings’ may rely on data that are 
collected during routine care.  Previously these were not likely to include preference-based 
measures of HRQL, although this may change with increased emphasis on patient reported 
outcome measures tied to reimbursement mechanisms.47  In the absence of a preference-
based measure of HRQL it may be possible to predict this from available clinical, disease-
specific measures.48-50  Prediction models for this purpose have been referred to as ‘cross-
walks’ or ‘mapping algorithms’.48  The internal validity of such an approach relies on an 
assumption that the observed measures capture the same information as would have been 
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measured by the generic preference-based measure.  A judgement about external validity is 
also required if a mapping algorithm is to be applied in a different patient population to that 
in which it was developed.  The predicted values are more uncertain than directly observed 
measures; this is in part captured in the standard error of the prediction equation but can 
also stem from structural uncertainty as to the most appropriate form of equation.51   
 
Another consequence of a more naturalistic setting may be an increased likelihood of 
missing observations compared to the more closely regulated RCT setting.  Unless the data 
are missing completely at random (MCAR), a simple complete case analysis will be biased.  
This is due to systematic differences between the observed values and the values of the 
missing observations such that the summary statistics of the complete observations are not 
expected to equal those of the overall sample.46  If the value of the missing observations is 
dependent on other observed values, the data can be said to be missing at random (MAR).  
While the assumption of MCAR can be proven inappropriate, no test can verify the 
assumption of MAR, so this relies on judgement about the mechanism for missingness.  If 
data are MAR, regression analysis can be used to predict the missing values in order to 
correct for bias.52 53  Using a single imputed value for each missing observation would 
underestimate the uncertainty and sampling error by giving imputed values equal weight to 
observed values even though their true value is predicted with uncertainty.  To correct this 
Rubin proposed multiple imputation of missing values and corresponding rules for the 
calculation of summary statistics that account for the additional uncertainty introduced by 
the imputation procedure.52 54 If data are missing not at random (MNAR), the probability of 
an observation being missing depends on its true value and the mechanism of missingness 
must be modelled to correct for bias.   
   
2.4. Utilising observational data on treatment effect 
Paper 11 illustrates how observational data collected in a naturalistic setting can be used in 
an economic evaluation by correcting for the potential biases described above while 
characterising the remaining uncertainty.  The study describes the primary analysis of 
observational data, missing data and the prediction of HRQL data where it has not been 
measured directly.  The ACRE study55 design sought to address the question of whether 
medical management, coronary artery bypass grafting (CABG) or percutaneous coronary 
intervention (PCI) might be cost-effective treatments for coronary heart disease in a 
patient population who, due to the characteristics of their heart disease, were excluded 
from previously conducted randomised trials, and for whom those same characteristics 
indicated that the results from available randomised trials may not be pertinent.  Despite 
their exclusion from the randomised trials of efficacy, published clinical guidelines indicated 
that CABG and PCI were clinically appropriate for some of these patients, and 
correspondingly they received them in routine UK practice.55  However, there was 
considerable uncertainty as to whether the magnitude of any health gains offered by these 
procedures, especially when provided after a waiting time exceeding that observed in 
previous trials, justified the considerable additional upfront expense relative to ongoing 
medical management.  The judgement about which evidence was relevant was that the 
external bias from relying on a dissimilar patient population able to be recruited to RCTs 
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exceeded the potential for internal bias from analysing data from a quasi-experimental 
study design.   
 
The ACRE study included a generic preference-based measure of HRQL at six years, but 
not at baseline or one year when only disease specific questionnaires were available.  In 
order to estimate QALYs a regression analysis was specified to predict EQ-5D score56 on 
the basis of angina, coronary heart disease measures of quality of life and other covariates.  
This generated a mapping algorithm that could be described as self-contained because it 
was estimated within-study, using information from the same population in whom it would 
be used to generate predictions.  This meant that internal validity could be assessed and 
external validity was not of concern; however, the use of multiple covariates could make it 
difficult to re-use for another study.50  Missing data were addressed using multiple 
imputation on the assumption that they were MAR.57  Selection bias was addressed by 
identifying a matched set of patients based on their assessed clinical appropriateness for 
each of the procedures.58  To control for potential remaining confounding factors 
regression analysis was used to estimate the differences in within-trial costs and QALYs 
attributable to each treatment.    Uncertainty was characterised by using seemingly 
unrelated regression to capture the correlation between costs and health outcomes.59 
 
The importance of study design in establishing the quality of evidence may vary with the 
characteristics of the intervention or the nature of the parameter to be informed.60  The 
analytical frameworks reflected in many of the existing guidelines for economic evaluation 
were developed with the focus on health care technologies and, in particular, 
pharmaceutical interventions, provided within the health care sector.32 61  The approach 
demonstrated in Paper 11 may have increased value as national reimbursement agencies 
take on responsibility for evaluating public health interventions which are less likely to be 
evaluated using RCTs, as are non-pharmaceutical interventions such as devices and 
diagnostics.42 62  A limitation of the analysis presented in Paper 11 is the reliance on a single 
data source.  Rarely will a single source of data be all that is available to inform an 
economic evaluation.63  The next section discusses how an economic evaluation may 
incorporate multiple sources of evidence.  
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3. Combining multiple sources of evidence 
A scientific approach to utilising available evidence can be used to support or justify societal 
level decisions about resource allocation.64  The evidence base to inform an economic 
evaluation of health care interventions can be large.  In order to evaluate the cost-
effectiveness of a particular technology it must be compared to all feasible alternatives and 
so the evidence base may include data collected on a number of interventions.  The cost 
and health differences resulting from the use of alternative treatment options may extend 
across a patient’s lifetime, or perhaps even multiple lifetimes if inter-generational effects are 
considered.  Thus relevant evidence may include data on the long-term prognosis of 
patients and information on the duration of treatment effects.  A range of study designs 
may be relevant depending on the nature of the parameter to be informed.  For example, 
RCTs might be the preferred source of data to inform estimates of treatment efficacy, 
while the cost of providing an intervention in practice may be derived from administrative 
data sources and evidence for the HRQL associated with a particular health state may be 
validly sourced from an observational study design.  In order to identify the range of 
available evidence in a transparent and replicable manner, techniques for systematic review 
are used.65 66  To conduct a systematic review a set of desirable criteria for included studies 
are defined against which those identified in a literature review can be assessed, first by 
determining whether they should be included in the review and then by assessing the 
quality of those eligible for inclusion.  The issues addressed in Section two exemplify how 
the inclusion criteria and quality assessment might be considered for studies to inform 
estimates of treatment effects.  The resulting set of identified evidence can then be brought 
to bear on the decision problem. 
       
3.1 Multiple sources of evidence providing the same information 
Methods for meta-analysis enable the synthesis of multiple sources of evidence on single 
parameters or even multiple parameters.67-70  The results of a series of studies are 
combined to provide a single overall estimate that describes the combined weight of 
evidence, with the contribution of each individual study weighted according to its precision.  
In its simplest form a number of controlled studies making the same pairwise comparison 
between interventions are combined.  However, where two or more active treatment 
options exist it is not unusual to observe a series of RCTs that include different sets of 
comparators.  If all relevant treatments have not been compared directly within a single 
trial, then the choice between treatments must be based on an indirect comparison.71  
Under these circumstances techniques for network meta-analysis enable multiple treatment 
comparisons by synthesising a series of studies linked by common comparators.72-74   
 
The fundamental assumption underlying all meta-analyses relates to the exchangeability of 
the relative treatment effects measured in different studies.  In a fixed-effects meta-analysis 
the assumption is that the same relative treatment effect would be observed, subject to 
stochastic variation, if the same comparison was made in any of the trial populations.  In a 
random-effects meta-analysis the population value of the relative treatment effect is 
assumed to vary between studies but to be drawn from a common distribution.   
Techniques for meta-regression can be used to assess whether study-level covariates 
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explain systematic differences in the relative treatment effect measured in different trials, 
but such methods are often underpowered in practice by the small number of the studies 
to be pooled.75  The assumption of exchangeability must be correct in order for the pooled 
estimate to have internal validity.  Problems with validity can arise when the availability of 
study results is correlated with the value of those results such that the synthesised studies 
are not a representative sample of all of the studies conducted.  As covered in Section two, 
data that are not MCAR must be addressed and techniques such as funnel plots, trim and 
fill, regression methods and selection models are among those that have been used to 
identify and address the issue of missing studies (publication bias) in the context of meta-
analysis.76 
 
It can be more difficult to test the assumption of exchangeability in a network of trials 
compared to a set of trials that each make the same comparison.  It is perhaps for this 
reason that many analysts and policy makers would choose to focus solely on direct data 
when both indirect and direct data are available.77 78  However such an approach could lead 
to the exclusion of many relevant studies.  For example, if two treatments are developed in 
parallel and each subject to a series of placebo controlled trials, a single trial comparing 
each head to head may represent only a small portion of the available evidence.  Excluding 
relevant data could lead to the value of a further data collection being overestimated.  
Good quality indirect evidence can provide more information and alter estimates of 
decision uncertainty even where comparable direct evidence is available.79 80  For this 
reason the exclusion of indirect data should not be the default position.  Instead, if there is 
uncertainty about whether the trials providing indirect data are exchangeable with those 
providing direct data, the analyst must judge whether the benefits of including the additional 
data outweigh the consequences of potentially introducing bias.  With more than two 
treatments under comparison, the same trial can provide both direct and indirect evidence 
and hence indirect evidence cannot be excluded from the analysis.  If the assumption of 
exchangeability is appropriate, the trial estimates will be consistent and there will be a 
transitive relationship between the true underlying treatment effects (measured on some 
appropriate scale).  This can be used to derive tests for consistency.81  Inconsistency within 
the network will lead to the indirect comparison increasing uncertainty and may raise 
concerns about the validity of the underlying assumptions.73 74   When the quantity of direct 
evidence is large, indirect evidence, which is automatically down-weighted in the analysis by 
having a larger variance, will have less impact on the pooled statistics compared to a 
situation in which less direct evidence is available.  Thus the value of expanding a network 
to include more indirect evidence will vary with the particular decision problem.  As 
identified studies become more distant from the comparison of interest, the evidence they 
provide is more indirect and has less impact on the pooled statistics.  This leads to 
diminishing returns in terms of increased accuracy from widening the network of included 
studies, which must be balanced against the opportunity cost of increased analysis time.   
 
Paper 22 demonstrates the method of a mixed treatment comparison for synthesising data 
from three RCTs, each evaluating a different pair from a set of three comparator 
treatments.  Each RCT provided a unique pairwise comparison in a complete network, 
meaning, firstly, that indirect data could not be excluded from the analysis; and, secondly, 
that consistency could be assessed within the set of trials.  However, a test for consistency 
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would not identify which of the three trials might not be exchangeable with the others as 
removing any one trial from the synthesis would eliminate inconsistency.  One of the trials 
was different in that it was stopped early due to recruitment problems and consequently 
had shorter follow-up and was never published in a peer-reviewed journal.  Presenting the 
results of pooling different subsets of the trials in a series of scenarios allows the decision 
maker to decide informally which set of trials may be most relevant to the decision 
problem.  A more formal approach would be to weight the trials in the synthesis not only 
according to sample size, but also according to some assessment of quality or relevance, 
thus incorporating that additional uncertainty in the final pooled estimates.  Extending 
evidence synthesis methods to include studies of differing quality or networks of evidence 
without a common comparator is practicable when using a Bayesian approach.82 83  Such 
methods could have allowed the economic analysis in Paper 11 to draw on evidence from 
both observational and RCT designs.84  However, this is an area of ongoing methodological 
work and consensus about how to determine appropriate weights has not yet been 
achieved. 
 
3.2 Multiple sources of evidence providing a range of information 
The trial data synthesised in Paper 22 provided estimates of progression free and overall 
survival from ovarian cancer.  These do not fully describe the outcomes of interest to 
patients, who may be interested in overall survival and HRQL, and do not describe the 
outcomes of interest for decision makers who may wish to compare the health gains 
achievable with treatments for ovarian cancer to those generated in other disease areas.  
For these reasons the meta-analysis represented only a portion of the relevant evidence 
base, as additional information was also required on long-term prognosis, costs and HRQL.  
The need to incorporate all relevant evidence, to compare all appropriate comparators 
over a suitable time horizon, and to bring together multiple sources of evidence across a 
range of parameters, can be facilitated with the use of a decision analytic model.63 85-87  Such 
models specify mathematical relationships between the various data sources to provide a 
quantitative assessment of cost-effectiveness that directly addresses the decision problem.  
They provide an explicit framework that should make clear the assumptions and logical 
relationships between inputs that determine the final outputs.88  Paper 22 utilised a simple 
cohort model that relied on an assumption of exponentially distributed survival times to 
convert hazards to mean survival, weighted by HRQL, and incorporated the costs of 
treatment and adverse events.89  In general, the appropriate design of such models depends 
on the decision problem to be addressed and the characteristics of the available data.90-92  
A model framework can be developed based on knowledge of the disease area and 
intervention, the data appropriately analysed for that framework and finally the outputs can 
be assessed in terms of validity to see whether modifications are required.93  Keeping 
models as simple as possible (i.e. being parsimonious in design) is a desirable property as it 
aids communication and transparency.92  The choice of more complex modelling 
approaches that increase analysis time should be justified in terms of increased accuracy in 
results.94  Models must be understandable to both technical experts and policy makers if 
they are to be useful and used in informing resource allocation decisions.95 
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Some assessment of model validity can be made on the basis of how accurately a decision 
model represents the source data.  With a single data source it may be possible to split the 
data into estimation and validation samples,96 but this requires large samples and is 
infeasible in the context of a decision model that relies on aggregate level data.  However, 
it is a model’s predictive ability that is of interest when informing policy choices.95  If an 
economic evaluation incorporates all available evidence or extrapolates beyond available 
data, there is no external data source against which to validate the resulting estimates of 
costs and health outcomes, even though such validation seems desirable.97 98  The face 
validity or credibility of the model predictions can be assessed based on prior beliefs 
concerning plausible outcomes.96  While certain models may be ruled out as invalid, it is, in 
general, not possible to identify a ‘correct’ model, only ones that are believed to be 
useful.99   The choice between alternative modelling frameworks for the same decision 
problem relies in part on value judgements by the analyst and is an area of ongoing 
methodological development.100  The way in which uncertainty in these choices and the 
relative precision of the multiple sources of evidence can be reflected in decision models is 
the subject of Section four. 
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4. Characterising uncertainty 
There are numerous sources of uncertainty in cost-effectiveness analysis.101  When the 
inputs to decision models are informed by sample data the underlying population values are 
estimated with imprecision and the evidence supports a range of plausible values with 
varying degrees of likelihood.  Where direct data are unavailable to inform a particular 
parameter, a range of possible values can be obtained by eliciting beliefs from persons 
considered to have some capability for estimating relevant information.102 103  Each different 
parameter value would imply a different estimate of the expected costs and health 
outcomes for the interventions under comparison, and this has been referred to as 
parameter uncertainty.  The manner in which the multiple sources of evidence are 
identified and synthesised can be informed by the demands of the decision problem, the 
normative judgements underlying the analysis and finally the characteristics of the identified 
data.  However, while particular methods may be ruled out as inappropriate a single best 
approach may not be apparent.  This will, in part, be due to ignorance or a lack of 
understanding of the collection of physical mechanisms and processes to which the data 
relate, but will also stem from differences in value judgements, for example about the 
appropriate measure of HRQL.  The existence of alternative plausible characterisations of 
the mathematical and logical relationships between parameters and alternative definitions of 
the set of relevant evidence leads to modelling or structural uncertainty in estimates of 
cost-effectiveness.104   
 
4.1 Sensitivity analysis for parameter uncertainty 
Uncertainty can be propagated through to the results of a decision model, thus describing a 
range of values of costs and health outcomes that could be estimated from the available 
(uncertain) evidence.  This provides information as to how the results of the analysis would 
change for different assumptions and input values, and is termed sensitivity analysis.  A 
distinction can be made between value sensitivity and decision sensitivity.  Value sensitivity 
refers to the change in magnitude of the estimated costs and health outcomes as a result of 
a change in the value of the inputs.  Decision sensitivity focuses on changes in the health 
care intervention that is regarded as most cost-effective following changes in the value of 
the inputs.27  In this regard, if the most cost-effective alternative is the same for all possible 
input characterisations, the model results could be said to be robust or insensitive to those 
changes.  Providing information only on value sensitivity, that is the range of possible values 
for costs and health outcomes, could be regarded as inadequate for informing decisions.27  
Paper 22 illustrated this fact by describing an example where reduced uncertainty in the 
estimated treatment effects and consequently the range of the model outputs was 
accompanied by increased decision uncertainty. 
 
One-way and multi-way sensitivity analyses have been used to show the impact of varying 
parameter values within some plausible range.  Individual parameters or groups of 
parameters are set to alternative or extreme values and the corresponding model outputs 
recorded.  Tornado diagrams or spiderplots are among the common methods used to 
illustrate the resulting value sensitivity in model outputs.103 105  While these may indicate 
parameter values for which the decision could change, they fail to quantify the likelihood of 
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any particular combination of parameter values.  They fail to capture the variable support 
provided by the available evidence for alternative possible true values of uncertain empirical 
quantities.  Another disadvantage of such ‘one-at-a-time’ or local sensitivity analyses is that 
the remaining parameters are held at their base case values and so important combinations 
can be missed.106  When multiple deterministic sensitivity analyses have been conducted it 
can be difficult to summarise the combined impact of all the uncertainty.85  An alternative 
approach for assessing parameter uncertainty is to describe the range of possible values 
supported by the data by assigning probability distributions to parameters.  The selection of 
distributions should be chosen to reflect the characteristics of the parameter and of the 
data generating process, and should capture any dependence or correlation between 
parameters.  The combined uncertainty from all input parameters can then be reflected in 
the model results using probabilistic sensitivity analysis (PSA).27   
 
In Paper 11 bootstrapping the seemingly unrelated regression was used to conduct the 
PSA,107 but Paper 22 utilised a more common approach for conducting PSA within decision 
analytic models by means of second order Monte Carlo simulation.108 109  In a second order 
Monte Carlo simulation sets of random values are repeatedly drawn from all of the 
distributions assigned to input parameters and the corresponding model outputs recorded.  
This is a direct empirical approach for describing the distribution of model outputs as a 
function of variation in the model inputs.  Sufficient simulations must be carried out to 
adequately describe that distribution and to obtain stable mean estimates that would not 
vary significantly were the analysis to be repeated.  In practice this may require thousands 
of simulations.  Fewer simulations may be required with more directed sampling of the 
inputs, for example with Latin Hypercube Sampling.110  PSA is required to obtain unbiased 
mean estimates of costs and health outcomes for non-linear models where the expected 
value of the outputs cannot be derived from the expected value of the inputs.85 The 
resulting distribution of costs and health outcomes characterises the degree of parameter 
uncertainty in the cost-effectiveness results.  The decision uncertainty can then be 
summarised, for example by presenting the results in the form of cost-effectiveness 
acceptability curves that describe the probability of each alternative being the most cost-
effective.111   
 
4.2 Sensitivity analysis for other sources of uncertainty 
In some cases, differences between alternative assumptions and judgements can be 
expressed in the form of an additional parameter in the model and thereby incorporated in 
the PSA.104  When structural uncertainty is not parameterised within the model the 
decision uncertainty encapsulated by the probabilistic outputs will be incomplete.104  
Structural or modelling uncertainty can be addressed in one-way sensitivity analysis by 
reanalysing the decision model for each of set of plausible assumptions (scenarios).  This 
characterisation of uncertainty may be appropriate when assessing sensitivity to value 
judgements, for example to the choice of discount rate.  However, if more than one 
modelling approach is considered reasonable and each produces a different estimate of 
expected costs and health outcomes, it may be appropriate to use more sophisticated 
methods to characterise this uncertainty.104  Methods for Bayesian model averaging would 
allow representation of this structural uncertainty by combining the outputs of the 
- 13 - 
 
alternative models, generating results that could incorporate both parameter and structural 
uncertainty.112  To utilise this approach it is necessary to construct and analyse each 
appropriate model structure, thereby increasing analysis time.  It is also necessary to 
estimate the appropriate weight to assign to each approach.113  The increase in analysis 
time may be minimal with the choice between alternative regression analyses, but could 
increase if the construction of more than one type of decision analytic model is required.  
The representation of structural uncertainty within economic evaluation is an area of 
ongoing methodological work. 
 
4.3 The implications of model design for PSA 
When PSA is conducted by means of bootstrapping or Monte Carlo simulation, the results 
of the decision model are repeatedly calculated.  For some models a lengthy analysis time is 
required for PSA and, in these computationally expensive models, PSA has in the past been 
regarded as unnecessary.3 88 114  A particular example is models that rely on a first order 
Monte Carlo simulation in order to represent variability among patients as a way of 
estimating expected costs and effects.  Stochastic variation between patients does not 
inform decisions about cost-effectiveness and introduces statistical noise in the calculation 
of expected costs and health outcomes.  It may need to be included as a nuisance 
parameter where there is a non-linear relationship between a patient characteristic and the 
model outputs in order to obtain unbiased results.  One way to achieve this is by using a 
patient level simulation or an individual sampling model, but sufficient simulations must be 
run to overcome the noise and to provide a stable estimate of costs and health outcomes.  
This use of first order Monte Carlo simulations to represent variability can make a second 
order Monte Carlo simulation ‘computationally expensive’ in terms of analysis time.115  The 
total number of simulations required can be several orders of magnitude greater than with 
a cohort model that excludes stochastic variation by describing the experience of the 
average patient.   
 
In order to have impact on reimbursement decisions the results of an economic evaluation 
should be considered valid and be available in a timely fashion.116  Omitting a full 
characterisation of uncertainty in order to characterise variability may have seemed a 
necessary trade off to some but Paper 33 illustrated a range of alternative modelling 
approaches that retain the characterisation of variability while reducing analysis time to 
allow for a characterisation of uncertainty.  Among the methods discussed are direct 
analytical solutions, alternative modelling frameworks and the use of response surface 
models which utilise statistical models to describe changes in the model outputs as a 
function of changes in some or all of the input values based on a smaller sample of 
simulations.  However, these approaches are still not commonly applied and may prove 
more difficult to implement in more complex models.106 117  The use of approximations 
would also introduce another element of modelling uncertainty that is absent when the 
distribution of model outputs is empirically sampled.118  Ongoing methodological 
development to reduce the analysis time for computationally expensive models119 alongside 
improvements in computing capabilities should pave the way for a characterisation of 
parameter uncertainty to be routinely included in economic evaluations.  The benefits and 
importance of this are addressed in Sections five and six. 
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5. Informing the need for further research 
When decisions are made on the basis of uncertain information there is a possibility that 
subsequent evidence will indicate that the interventions reimbursed did not in fact 
represent good value for money.  The difference between the realised population health 
gains and those that could have been achieved by reimbursing the ‘true’ optimal set of 
health interventions represents the opportunity cost of uncertainty.  This opportunity cost 
is a function of the probability of error and the magnitude of the health outcomes forgone 
if the wrong decision is made.29  Further evidence is expected to reduce decision 
uncertainty, the probability of error and the expected value of this opportunity cost.120  A 
characterisation of uncertainty in the estimated costs and health outcomes is therefore 
relevant when we wish to address questions about the sufficiency of the current evidence 
base, and whether health gains could be achieved by allocating resources to fund further 
research.28  Economic evaluation can inform an assessment about whether current 
evidence is sufficient by quantifying the opportunity cost of uncertainty and the anticipated 
costs of acquiring further evidence.   
 
For this reason it is important to distinguish between variability and uncertainty.  Variability 
(aleatory uncertainty) arises from natural stochasticity and is irreducible through further 
research, as is heterogeneity in individual patient’s responses to treatments.  Uncertainty 
(epistemic) stems from incomplete knowledge and is, in principle, reducible through further 
measurement.121  For example, conducting an additional trial would be expected to 
increase the precision of the pooled estimate in a meta-analysis.  Similarly, further data 
collection can be used to validate modelling assumptions, reducing modelling uncertainty.96  
Where the expected health gains from acquiring additional information exceed the 
anticipated costs, a decision maker should, in principle, be willing to pay to obtain further 
evidence.  The limited availability of research funds means that it is not possible to fund 
every research study where the expected benefits of the additional information exceed the 
costs of conducting the research.  Hence methods are required to prioritise among 
alternative research designs, and utilising the results of a probabilistic model could provide 
a means to achieve this.26 28 122-126 127 
 
5.1 The value of perfect information 
The value of an error-free choice can be estimated by supposing that we can select the 
optimal intervention in every possible future state of the world.  Comparing these 
maximum health gains that assume perfect knowledge to those expected under uncertainty 
provides the expected value of perfect information (EVPI), which represents the upper 
bound on the value of further evidence.  This quantity is readily estimated from the results 
of a PSA as the distributions assigned to parameters describe the range of possible true 
values and the associated distribution of expected costs and health outcomes is calculated.  
As information is non-rival, value is generated in every subsequent decision that would 
utilise the additional evidence.  Therefore, an estimation of the number of decisions is 
required to estimate the total value of research or population EVPI.128  In order for further 
research to be worthwhile it is necessary that this exceeds some minimal cost of research.  
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Consequently, for some decision problems, the current evidence may be deemed sufficient 
on the basis of low or zero estimated population EVPI.85 129 
 
Where the EVPI indicates that further research is potentially worthwhile, further questions 
can be addressed to determine what type of research may be valuable.  In order to 
establish which of the model inputs are associated with decision uncertainty it is possible to 
estimate EVPI for individual parameters or groups of parameters.120 130  The value of perfect 
information about a parameter provides another measure of sensitivity for judging the 
relative importance of uncertainty in the model inputs and can help determine more 
precisely what should be measured in future research studies.27  It is calculated in a similar 
way as overall EVPI by supposing that we can select the most cost-effective alternative for 
every possible value of the parameter(s) in question, but with the uncertainty unaltered in 
the remaining inputs.  This is readily obtained from the results of a PSA in linear models but 
requires an additional level of Monte Carlo simulation for non-linear models and 
consequently increased analysis time.131 132   
 
The study design appropriate for providing additional information will vary according to the 
characteristics of the parameter in question, as will the costs of carrying out the research.  
A lengthy research design will be able to benefit fewer patients, and a more costly research 
design will have lower net benefits as it will displace either treatments that would have 
generated health gains or alternative research studies that could have generated health 
gains.  Paper 44 describes methods for evaluating the value of information for a range of 
different research designs.  Those previously described in the literature focussed on 
estimating the value of further information for particular parameters or groups of 
parameters within the decision model.27 31 133-135  A prioritisation of research based on the 
value of alternative ‘one-off’ research designs might suggest that the study with the greatest 
individual expected health gains net of research cost be funded.  However, this assessment 
would be incomplete.  In general, the relative value of any particular research design should 
be evaluated against the full range of alternative research designs.122 127 136  Paper 44 reviews 
existing approaches and extends the methods to evaluate a sequence of research to 
incorporate the impact that additional research on one parameter will have on the 
expected value of further information about the remaining parameters.  The strategic value 
of a sequence of research is obtained when information that can be obtained relatively 
cheaply about one parameter indicates that a previously valuable more costly research 
design is unnecessary.  In these circumstances the first study may not warrant prioritisation 
on its own merit.  However, the value of a sequential research design is largely based on 
avoiding research designs with high opportunity costs, meaning there is a clear need to 
estimate accurately the costs of the proposed research designs and this may require an 
assessment of the optimal sample size as well as the research design.136 137  This would 
require estimation of the value of sample information.130   
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5.2 The value of sample information 
In practice, further evidence will reduce rather than eliminate uncertainty.  The principle 
underlying the estimation of the expected value of sample information (EVSI) is the same as 
that for EVPI.  The results of the intended future study must be predicted in order to 
calculate the expected health gains from a decision that incorporates that additional 
information.130  This value is compared to the expected health gains from a decision based 
only on current evidence to estimate EVSI.  The expected cost of the proposed research 
design is subtracted from the EVSI to provide the estimated net benefit of sample (ENBS) 
information.  A positive ENBS provides a sufficient condition for conducting further 
research.  However, when the results of further studies are predicted by means of Monte 
Carlo simulation the required analysis time can be very high unless the underlying model is 
very simple.  Applications demonstrating the calculation of ENBS typically feature linear 
models with few parameters or are restricted to comparisons of two interventions where 
the new study is assumed to update the estimated incremental net benefits directly.31 136  
While methodological work is continually suggesting ways to reduce analysis time for more 
complex scenarios,138 currently the widespread application of methods to prioritise 
between research designs, such as those discussed in Paper 4,4 may rely on EVPI, meaning 
they act only as a guide to decision making.125   
 
5.3 Realising the benefits of research 
The health benefits of research are realised when they are translated into treatment 
decisions.  Decisions about reimbursement and research should be made on the same 
basis, as both have the same objective to improve population health gains and both place 
demands on the resources available within the health care system.29 139  The use of 
economic evaluation to inform research designs can ensure that the information collected 
directly addresses the decision uncertainty.  However, some caution should be exercised 
when using PSA to inform the need for further research as this could give undue weight to 
uncertainty that is easily characterised by means of probability distributions at the expense 
of other sources of uncertainty.99  The methods for valuing research designs described 
above assume full implementation of the health care intervention identified as most cost-
effective.  If in practice implementation is variable, this should be reflected in the 
calculations and requires some assessment of how further evidence would change clinical 
decisions.127 140 Alternatively, the decision maker may wish to invest in strategies to alter 
clinical practice.141  The impact of investment costs when reimbursement decisions are 
made on the basis of uncertain evidence is considered further in Section six which 
discusses the consequences of uncertain decisions. 
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6. The impact of uncertainty on reimbursement decisions 
The evidence available to inform any decision is not static.  As new evidence emerges 
economic evaluations can be updated and reimbursement decisions reconsidered.142 143  If 
the decision to reimburse a health care intervention could be changed instantaneously and 
without cost as new information arrives, then the probability of executing those changes 
would be inconsequential.30  However, this may not be the case in practice, and revising 
decisions may be impossible (irreversible) or costly.  When there are resource implications 
associated with implementing and reversing decisions, a characterisation of uncertainty is 
required in order to estimate the consequences of that uncertain decision.  Increasingly 
reimbursement decisions about new interventions are extending beyond simple approval or 
rejection, to consider a range of policy options that incorporate by design some response 
to decision uncertainty.  For example the use of risk-sharing or patient access schemes may 
make the price paid for the technology conditional on the realised health gains.144  
Alternatively a decision may be linked to evidence collection by limiting reimbursement to 
patients included in research trials or by making reimbursement conditional on the 
provision of further information.145-147 To inform the optimal use of these kinds of 
reimbursement decisions, a characterisation of uncertainty is always relevant and essential. 
 
6.1 Incorporating investment and reversal costs 
Investment costs that are sunk cannot to be recovered if a decision is changed.  These may, 
for example, include the costs of training and persuading clinicians to deliver a new 
intervention.  Such costs are relevant to, and should be incorporated when, assessing 
whether a new health care intervention is cost-effective.  Typically this has been achieved 
through annuitisation, where up-front investment costs are converted into annual 
equivalent outlays across the useful life span of the asset in question.148  For a piece of 
capital equipment the useful lifespan is simply the time until a replacement for the machine 
is required.  The equivalent annual outlay should take account of the resale value 
(recoverable cost), reflecting the depreciation of the asset and the opportunity cost of the 
funds tied up in the asset.148  For training costs the relevant life span is the time until the 
treatment decision is altered to one for which the training is irrelevant.  The additional 
health gains expected by switching to a new intervention must be accumulated in sufficient 
patients to outweigh any up-front investment costs in order for an intervention to be 
regarded as cost-effective.  Reversal costs are incurred only if the treatment decision is 
altered, and may include the dissemination of information on the policy change or political 
costs if it is accompanied by a loss of credibility.  For reimbursement decisions informed by 
economic evaluations, changes would be precipitated by the arrival of new evidence.128 142  
Some assessment of the prospect that further evidence would alter the optimal treatment 
decision, such as that provided by PSA, is therefore required in order to appropriately 
incorporate investment and reversal costs in estimates of cost-effectiveness.  This should 
be accompanied by some estimate of the timing of those changes.5 128  By deferring a 
decision until uncertainty is reduced, investment costs can be avoided or mitigated.  This 
describes the option value of delaying a decision, which will vary according to the degree of 
uncertainty and irreversibility associated with the particular decision problem.30  This 
option value should be compared to the opportunity costs of delaying access to potentially 
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cost-effective health care technologies in terms of the health forgone by patients who, in 
the meantime, receive an intervention expected to be less cost-effective.29 149 150   
   
6.2 The impact of reimbursement on the prospects for research 
The option value of delay could be used to inform a decision to await the arrival of new 
evidence.  Alternatively a decision maker with control over both reimbursement and 
research decisions could use an economic evaluation to inform simultaneous decisions 
about both.31 149 151  Whether decision makers take an active or a passive role in the 
generation of new evidence, the impact of reimbursement on the incentives for further 
research must be considered.  Once approval for reimbursement is granted manufacturers 
are no longer likely to retain an incentive to provide further evidence for the technology in 
question.  Furthermore, randomising new patients to ongoing or new trials may prove 
difficult or be deemed unethical once an intervention is recommended for widespread use.  
While additional trials may still be feasible outside the jurisdiction if other countries have 
not yet approved the intervention, that evidence may not be able to reduce decision 
uncertainty if differences in patient population or health care systems limit 
generalisability.152 153  A negative reimbursement decision may also limit the feasibility of 
further research, for example if additional evidence is desired on rare adverse events.  Thus 
reimbursement decisions may result in the forgoing of further research.  Only with 
estimates of the decision uncertainty can this potential opportunity cost, that is the 
potential value of information forgone, be evaluated.  Paper 55 demonstrated these issues 
and proposed an amendment to existing decision rules based on expected cost-
effectiveness that would incorporate this opportunity cost of value of information forgone. 
 
6.3 Linking reimbursement with uncertainty 
Incorporating the option value of delay in reimbursement decisions means that 
interventions associated with greater uncertainty and irreversibility are less likely to be 
approved for reimbursement on the basis of current available evidence than under a 
decision rule that ignores this opportunity cost.30 Taking account of the impact of the value 
of information forgone would further decrease the likelihood of immediate approval for 
technologies associated with greater uncertainty where the ability to resolve that 
uncertainty was impaired by the decision to reimburse.5  By incorporating uncertainty in 
reimbursement decisions a different optimal set of health interventions is identified 
compared to decision rules based on expected costs and health outcomes.  The 
importance of incorporating uncertainty is increased further when decisions about whether 
to approve a health care technology for reimbursement extend beyond a simple approval 
or rejection.  Decisions about reimbursement are increasingly made jointly with a decision 
about pricing (e.g. patient access schemes) that aims to mitigate the impact of decision 
uncertainty.144  These schemes reduce the effective price of a technology, making it more 
likely to appear cost-effective.  A characterisation of uncertainty is required in order to 
assess the extent of the effective price reduction, and allow any savings to be compared to 
the potential transaction costs of implementing such schemes.154  Paper 55 showed how 
price adjustments can impact not only on the value of immediate access to a new 
treatment, but also on the value of further research, further altering the balance between 
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immediate approval and deferral.  Another aim of risk-sharing schemes is to allow the 
collection of further data alongside use to support the reimbursement decision.  The type 
of data that can be collected while a technology is approved for widespread use may be 
restricted in practice for the reasons addressed above.  Consequently the feasibility of such 
schemes to reduce decision uncertainty may depend on the type of evidence required, the 
assessment of which was discussed in Section five.  The need for randomised evidence 
could imply that technologies should be approved for use only within the context of a 
research study.145  Even with such schemes the completion of further research is not 
guaranteed,155 156 and the methods proposed in Paper 55 allow for the incorporation of 
uncertainty as to when and whether further evidence will become available. 
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7. Summary 
The papers presented within this thesis cover a range of issues relevant to the 
characterisation of decision uncertainty in the economic evaluation of health care 
interventions.  Together, the first four Sections of this Integrative Chapter provide an 
overview of how uncertainty can be incorporated in economic evaluations.  This requires 
consideration and judgement about how the available evidence actually relates to the 
decision problem.  Section two considered the problem of identifying relevant evidence on 
the causal effects of interventions.  Details of analytical methods to address concerns about 
internal validity, by correcting for selection bias in observational data sources and 
addressing missing data, were described, in addition to methods for translating clinical 
outcomes into those required for economic evaluation.  Paper 1 showed how these 
methods could be combined and used jointly to perform cost-effectiveness analysis when 
concerns about external validity meant that data from RCTs was considered irrelevant and 
available data sources failed to include all outcomes of interest for economic evaluation.  
The analysis simultaneously corrected for multiple potential sources of bias, and estimated 
outcomes on a scale that was appropriate for informing reimbursement decisions.  The 
approach exemplified in Paper 1 is applicable to a wide range of health care technologies, 
demonstrating that the use of economic evaluation need not be limited to decisions about 
pharmaceutical or clinical interventions or about patient populations who are represented 
in RCTs.   
 
Section three described how the weight of evidence could be assessed by combining 
information from a range of sources.  Paper 2 showed how techniques for network meta-
analysis could be applied to a series of studies that did not feature a common comparator 
in order to provide a single summary estimate of cost-effectiveness.  The results 
demonstrated how different judgements about which sources of evidence are relevant 
could impact on estimates of cost-effectiveness.  By enabling all available studies to be 
synthesised simultaneously, the methods demonstrated in Paper 2 allowed the question of 
the relevance of available studies to be based on an assessment of their relative merits, and 
not driven or constrained by the method of analysis.  This can ensure that economic 
evaluations reflect the judgements of the decision makers they seek to inform.   
 
Section four provided a technical description of how uncertainty and the weight of 
evidence can be characterised within decision analytic models.  The focus was on how to 
summarise the decision uncertainty, and in particular the use of PSA for reflecting the 
combined impact of uncertainty in the model parameters.  To this end Paper 3 illustrated 
some amendments to decision models that would mean that a full assessment of decision 
uncertainty was not curtailed by available analysis time.  The methods demonstrated in 
Paper 3 can help ensure that the information provided by economic evaluations is driven by 
the needs of decision making and the requirements of the decision problem, and not 
constrained by the choice of modelling approach.   
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The importance of assessing decision uncertainty was discussed in Sections five and six.  
Section five showed how an assessment of decision uncertainty could be used to inform the 
design of further research to reduce that uncertainty, thereby improving treatment 
decisions and expected health outcomes for future patients.  Paper 4 advanced existing 
methods by showing how the value of a sequential research design could be estimated.  
Utilising the methods described in Paper 4 to evaluate a more comprehensive range of 
potential research designs would ensure that the appropriate opportunity costs are 
reflected in economic evaluations that seek to inform the prioritisation of further research.   
 
Finally in Section six, the various consequences of decision making under uncertainty were 
considered.  The first was that the optimal reimbursement decision would change over 
time with the arrival of new evidence.  When this was combined with investment or 
reversal costs it was illustrated that a characterisation of uncertainty was essential to 
identifying the optimal set of health interventions to reimburse.  Paper 5 demonstrated 
how reimbursement decisions can impact on the prospects for further research, and that 
the value of information forgone is an irreversible aspect of reimbursement decisions.  The 
methods presented in Paper 5 showed how this opportunity cost could be estimated and 
how it would alter decisions about which treatments should be adopted in order to 
maximise population health gains.  Paper 5 provided a clear set of arguments as to why 
failing to incorporate the impact of decision uncertainty in reimbursement decisions would 
lead to health gains not being maximised, and showed that this was the case even when 
economic evaluations are used to inform decision makers whose remit is limited to 
approval or rejection of technologies for reimbursement.  The framework presented in 
Paper 5 can be used to illustrate the impact of price adjustments on both assessments of 
cost-effectiveness and the need for further research, and can incorporate uncertainty in 
when and whether further research will report.  The strength of the framework is that it is 
relevant to a wide range of decision problems, particularly when economic evaluations are 
used to inform reimbursement decisions made jointly with decisions about pricing or 
further evidence collection. 
 
It is not yet possible to fully characterise all uncertainty within an economic evaluation or, 
for example, to routinely implement some of the more complex but theoretically feasible 
analyses discussed in this thesis.  Nevertheless an economic evaluation that incorporates a 
characterisation of known or agreed uncertainties can provide a useful aid to decision 
making.  Uncertainty is inherent in decisions about resource allocation regardless of how 
they are made, but by conducting a formal analysis the range of sources of uncertainty can 
be made explicit, and their impact on subsequent decisions made transparent.  This can 
help ensure that decision makers are held accountable for their choices concerning the 
allocation of collective resources by the people on whose behalf they are made, by making 
clear the reasoning and judgements underlying those decisions.  It can also help to ensure 
that the response to uncertainty is consistent across decisions made at different times or 
for different groups.  Continued testing and development of the methods for characterising 
uncertainty in economic evaluations can ensure that the analyses provide information that 
is useful, timely and relevant to the decision problems they seek to inform.  
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RESEARCH
Cost effectiveness of clinically appropriate decisions on
alternative treatments for angina pectoris: prospective
observational study
S C Griffin, research fellow,1 J A Barber, lecturer in medical statistics,2 A Manca, Wellcome Trust training
fellow in health services research,1M J Sculpher, professor of health economics,1 SGThompson, professor of
medical statistics,3 M J Buxton, professor of health economics,4 H Hemingway, professor of clinical
epidemiology5
ABSTRACT
Objective To assess whether revascularisation that is
considered to be clinically appropriate is also cost
effective.
Design Prospective observational study comparing cost
effectiveness of coronary artery bypass grafting,
percutaneous coronary intervention, or medical
management within groups of patients rated as
appropriate for revascularisation.
Setting Three tertiary care centres in London.
Participants Consecutive, unselected patients rated as
clinically appropriate (using a ninemember Delphi panel)
to receive coronary artery bypass grafting only (n=815);
percutaneous coronary intervention only (n=385); or both
revascularisation procedures (n=520).
Main outcome measure Cost per quality adjusted life year
gained over six year follow-up, calculated with a National
HealthService cost perspective anddiscountedat 3.5%/year.
Results Coronary artery bypass grafting cost £22000
(€33000; $43000) per quality adjusted life year gained
compared with percutaneous coronary intervention
among patients appropriate for coronary artery bypass
grafting only (59% probability of being cost effective at a
cost effectiveness threshold of £30 000 per quality
adjusted life year) and £19 000 per quality adjusted life
year gained compared with medical management among
those appropriate for both types of revascularisation
(probability of being cost effective 63%). In none of the
three appropriateness groups was percutaneous
coronary intervention cost effective at a threshold of
£30000 per quality adjusted life year. Among patients
rated appropriate for percutaneous coronary intervention
only, the cost per quality adjusted life year gained for
percutaneous coronary intervention compared with
medical management was £47000, exceeding usual cost
effectiveness thresholds; in these patients, medical
management was most likely to be cost effective
(probability 54%).
ConclusionsAmongpatients judged clinically appropriate
for coronary revascularisation, coronary artery bypass
grafting seemed cost effective but percutaneous coronary
intervention did not. Cost effectiveness analysis based on
observational data suggests that the clinical benefit of
percutaneous coronary intervention may not be sufficient
to justify its cost.
INTRODUCTION
Guidelines based on clinical appropriateness criteria
(optimising net benefits to health) are widely used to
inform decisions about practice but are insufficient
grounds for allocating healthcare resources. Although
consensus exists that cost effectiveness analysis is
needed to maximise the health gains achieved from a
limited budget, how closely formallymeasured clinical
appropriateness accords with cost effectiveness is not
known. Population rates of coronary revascularisation,
particularly percutaneous coronary intervention,1
have increased rapidly, but many influential trials
report no cost data,2 analyse costs but not in relation to
effectiveness,3 or report cost effectiveness but not in
terms of quality adjusted life years.4 No three way ran-
domised comparisons of the cost effectiveness of med-
ical management, percutaneous management, and
coronary artery bypass grafting exist.2 Most impor-
tantly, as clinical equipoise is seen as an ethical prere-
quisite of randomisation, patients considered clinically
more suitable for one procedure than another are, gen-
erally, not included in trials.
We sought, therefore, to identify the cost effective-
ness of treatments rated as clinically appropriate by a
multidisciplinary panel. We studied three alternative
management strategies for coronary disease: coronary
artery bypass grafting, percutaneous management,
and medical management. We used the RAND
appropriateness method,5 which has been shown to
be a prognostically valid method to determine the
clinical suitability of unselected patients to have
revascularisation,67 but without consideration of
costs. A cost effectiveness analysis based on quality
adjusted life years is suitable for comparing treatments
that are expected to affectmortality,morbidity, or both
and is the most suitable basis to inform decisions
about the provision or reimbursement of healthcare
technologies.8
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METHODS
Participants
The appropriateness of coronary revascularisation
(ACRE) cohort consists of consecutive patients,
recruitedwithout exclusion criteria, who had coronary
angiography between 15April 1996 and 14April 1997
at three hospitals of one National Health Service trust
in London.5 We identified 4121 patients and followed
them for six years.Most patients had chronic coronary
disease at baseline; only 6% were recruited during an
admission with acute myocardial infarction. This
economic evaluation focuses on the subgroup of 1740
patients rated as appropriate to have bypass surgery,
percutaneous management, or both. Of these, we
excluded 20 patients because they died without having
revascularisation and no record of their intendedman-
agement plan existed. All patients gave consent.5 A
detailed technical report of the methods used for this
six year analysis is available (www.york.ac.uk/inst/
che/staff/griffin.htm).
Clinical appropriateness ratings
Before recruitment of patients to the ACRE study, a
ninemember expert panel rated separately the clinical
appropriateness of bypass surgery and percutaneous
management in hypothetical patients for 985 specific
clinical indications (based on the RAND-Delphi
technique9). Appropriateness was defined by clinical
judgment, based on available evidence, that doing a
procedure would be associated with more benefit
than harm. Appropriateness ratings were assigned to
ACRE participants on the basis of their individual
clinical characteristics at the time of angiography to
identify those patients who would benefit clinically
from revascularisation. Details of these ratings have
been reported previously.10 The ratings did not take
account of patient preferences or cost considerations.
NHS resource use and costs
We adopted the cost perspective of the NHS and
included the costs of bypass surgery, percutaneous
management and angiography procedures (including
hospital stay), drugs, admissions for chest pain, general
practitioner visits, outpatient appointments, and visits
to the emergency department. The occurrence of hos-
pital admissions, their reasons, and lengths of stay
came from the NHS-wide clearing service. Data on
drugs at baseline and at one year and six year follow-
ups came from hospital case notes, general practi-
tioners’ and patients’ questionnaires (response rate
85% at baseline, 77% at one and six years), and case
notes after admissions for chest pain. Frequency of
attendance in the previous year at a general practice,
outpatient department, or casualty came from the
patients’ questionnaire. Unit costs came from pre-
viously published studies and published pricing lists
for the United Kingdom.311 12 Costs are reported in
UK sterling (£), updated to 2003/4 prices and
discounted at 3.5%/year.8 11
Outcomes and quality adjusted life years
More than 99% of the study sample were flagged with
the UK Office of National Statistics, which notified us
of dates of death. We ascertained acute non-fatal myo-
cardial infarction through the NHS-wide clearing
service and classified it according to recent criteria.13
As part of the six year questionnaire, patients com-
pleted the EQ-5D health related quality of life instru-
ment, fromwhichwederivedutility scores.14 15Utilities
represent quality weights for the calculation of quality
adjusted survival; 1 corresponds to the highest degree
of quality of life, and 0 is equivalent to dead. As we did
not collect EQ-5Ddata at baseline andone year follow-
up, we estimated utilities for these time points by using
other variables on the patients’ questionnaire to pre-
dict EQ-5D scores in a regressionmodel. The variables
used included the patient rated severity of angina
symptoms,16 shortness of breath, anddemographic fac-
tors. We calculated an estimate of quality adjusted sur-
vival for each patient by weighting their survival
according to their quality of life.Wediscounted quality
adjusted survival at a rate of 3.5% a year.8
Statistical methods
We analysed patients in three groups on the basis of
their being rated clinically appropriate for bypass
surgery only (that is, not for percutaneous manage-
ment), for both procedures, or for percutaneous man-
agement only (that is, not for bypass surgery). Within
the three groups, we compared those who had bypass
surgery, those who had percutaneous management,
and those who had neither type of revascularisation
(medical management). These actual management
groups are defined as the treatment received within
one year of index angiography. For patients who died
within one year without having a procedure, we used
the intended management recorded at baseline as a
proxy for actual management.
We used regression analyses with interaction terms
to estimate the effect of actual management, by appro-
priateness category, on cost effectiveness (total costs
and quality adjusted survival), presence of angina,
andmortality at six years’ follow-up.We adjusted ana-
lyses for the potential confounders in table 1, and addi-
tionally included baseline utility for adjustment of
quality adjusted life years.17 Odds ratios for presence
of angina at six years came from multiple logistic
regression and hazard ratios for death from Cox
regression. Regression of life years (cumulative survi-
val) used an ordinary least squares approach. We ana-
lysed cost effectiveness by using seemingly unrelated
regression,18 a multivariate regression technique that
accounts for the potential correlation between costs
and quality adjusted survival.
To compare the three management strategies, we
used standard cost effectiveness decision rules.19 We
calculated the incremental cost effectiveness ratio
comparing two management strategies, which repre-
sents the cost per quality adjusted life year gained by
moving to a more costly, more effective method of
management. To reflect uncertainty, we derived cost
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effectiveness acceptability curves showing the prob-
ability that each treatment is cost effective for a range
of threshold amounts that the NHSwould be willing to
pay per quality adjusted life year.20 We have used a
threshold of £30 000 (€45 000; $58 000) per quality
adjusted life year in presenting the cost effectiveness
results, on the assumption that the maximum incre-
mental cost effectiveness ratio acceptable to the NHS
lies between £20 000 and £40 000 per quality adjusted
life year.21
We imputed missing data on length of stay and
patient reported resource use (general practitioner vis-
its, outpatient attendances, and visits to casualty) with
simple ordinary least squares. In adjusted analyses, and
when obtaining utilities, we used multiple imputation
with chained equations.22 23We created five imputation
datasets to allow retention of between imputation var-
iance in estimating standard errors.24
Weusedunivariate sensitivity analyses to investigate
assumptions about the need to adjust for the definition
of actual management, the inclusion of patient
reported resource use, the exclusion of hospital admis-
sions for reasons unrelated to chest pain, and the differ-
ential timing of the one year patients’ questionnaire
(one year from revascularisation for percutaneous
management and bypass surgery or one year from
index angiography for medical management).
RESULTS
Baseline characteristics
Of the 1720 patients in the economic analysis, 815
(47%) were rated as appropriate for bypass surgery
only, 520 (30%)were rated as appropriate for both pro-
cedures, and 385 (22%) were rated as appropriate for
percutaneous management only (table 1). The preva-
lence of current smokers was similar across the three
appropriateness groups (10%, 10%, and 13%). The
severity of angina (Canadian Cardiovascular Society
class) was also similar. Those rated as appropriate for
bypass surgery tended to have a higher number of dis-
eased vessels, higher prevalence of impaired left ven-
tricular function, and higher operative risk scores.
Single vessel disease was more common among
patients rated as appropriate for percutaneous man-
agement only.
Clinical outcomes
Over the six year follow-up, 44% (335/754) of patients
initially treated with medical management and 26%
(93/364) of those initially treated with percutaneous
management went on to have additional revascularisa-
tion procedures; of those who initially had bypass sur-
gery, further revascularisation was needed for only 4%
(25/602) of patients. Angina was present in 55% (560/
1020) of patients at six years. Among patients rated as
appropriate for bypass surgery, adjusted analyses
showed a significantly raised odds of angina for those
who had percutaneous management or medical man-
agement comparedwith thosewho had bypass surgery
(table 2). A suggestion of similarly raised odds was
apparent in patients suitable for percutaneousmanage-
ment who had medical management compared with
those who had percutaneous management. Overall,
16% (277/1720) of patients died during follow-up.
Adjusted analyses in the group appropriate for bypass
surgery showed a raised risk of death for thosewhohad
medical management compared with bypass surgery
or percutaneous management. Among the group
rated appropriate for percutaneous management and
bypass surgery, we found some evidence that the risk
of death in patients who had percutaneous manage-
ment or medical management was almost twice that
in those initially treated with bypass surgery (table 2).
Costs
The costs of treating patients with medical manage-
ment remained considerably lower than those for per-
cutaneous management or bypass surgery (fig 1). In
year one, the costs of medical management were 9-
12% of bypass surgery costs and those for percuta-
neous management were 43-50% of bypass surgery
costs. By year six, these ratios rose to 43-50% for med-
ical management and 78-82% for percutaneous man-
agement, primarily owing to the need for additional
revascularisation procedures (table 2). Approximately
74% of percutaneous interventions involved one or
more stents. The average unadjusted costs of each
initial treatment strategy were, at baseline, £12 500
for bypass surgery, £5800 for percutaneous
Table1 | Baselinecharacteristicsbyappropriatenesscategory.Valuesarenumbers (percentages)
unless stated otherwise
Baseline covariate (No
missing)
Appropriate for CABG
only (n=815)
Appropriate for both
(n=520)
Appropriate for PCI only
(n=385)
Mean (SD) age (years) 63 (9) 59 (9) 59 (9)
Male 671 (82) 403 (78) 292 (76)
Ethnic group (141):
White 623 (83) 396 (84) 303 (85)
Other 130 (17) 76 (16) 51 (14)
Previous CABG 60 (7) 68 (13) 29 (8)
Previous PCI 31 (4) 62 (12) 45 (12)
Previous MI 371 (46) 268 (52) 207 (54)
Heart failure 116 (14) 48 (9) 44 (11)
Previous stroke 76 (9) 34 (7) 29 (8)
Diabetes 130 (16) 69 (13) 52 (14)
No of diseased vessels:
≤1 18 (2) 213 (41) 282 (73)
2 106 (13) 263 (51) 79 (21)
3 or left main stem 691 (85) 44 (8) 24 (6)
Diffuse disease 199 (24) 71 (14) 28 (7)
Left ventricular function (329):
Normal 456 (67) 324 (82) 251 (78)
Impaired 220 (33) 71 (18) 69 (22)
Mean (SD) Parsonnet operative
risk score37
7.3 (5.4) 5.2 (4.4) 5.8 (5.3)
CCS score (362):
0 (no angina) 38 (6) 22 (5) 14 (5)
I-II (mild angina) 179 (27) 97 (24) 76 (25)
III-IV (severe angina) 437 (67) 282 (70) 213 (70)
CABG=coronary artery bypass graft; CCS=Canadian Cardiovascular Society; PCI=percutaneous coronary
intervention; MI=myocardial infarction.
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management, and £1400 for medical management;
these rose to £16 200, £12 100, and £9200 at six years.
The adjusted analysis made little difference to the esti-
mated cost differences (table 3).
Cost effectiveness
Average predicted baseline utility was 0.55, consider-
ably lower than the UK population norm of 0.80 for
people aged 55 to 64.25 The average utility score
among those alive at six years improved to 0.65.
Because of deaths, the average length of survival in
the study was around five years. Adjusted analyses by
appropriateness category showed no significant differ-
ences in discountedmean survival duration (that is, life
expectancy) across treatment groups. For the groups
rated appropriate for bypass surgery only or percuta-
neous management only, the clinically appropriate
treatment had the highest mean quality adjusted life
years. In the group rated appropriate for either type
of revascularisation, bypass surgery had the highest
mean quality adjusted life years. Adjusted analyses
showed significant differences in quality adjusted sur-
vival comparing medical management with bypass
surgery in patients appropriate for bypass surgery
only or for percutaneous management and bypass sur-
gery (table 3).
Among patients rated as appropriate for bypass sur-
gery only, the incremental analysis showed that percu-
taneous management had an incremental cost
effectiveness ratio of £11 000 per quality adjusted life
year compared with medical management and bypass
surgery had an incremental cost effectiveness ratio of
£22 000 per quality adjusted life year compared with
percutaneous management (table 3). Thus bypass sur-
gery is the most cost effective procedure for patients
rated as appropriate for bypass surgery. The probabil-
ity that bypass surgery is the most cost effective treat-
ment strategy was 59% at a willingness to pay of
£30 000 per quality adjusted life year, compared with
40% for percutaneous management (fig 2).
In patients rated as appropriate for both procedures,
percutaneous management was ruled out on grounds
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Fig 1 | Unadjusted total cost: mean annual and cumulative cost
by actual management and appropriateness category. Costs
presented in 2003/4 UK sterling, discounted at 3.5% a year.
CABG=coronary artery bypass surgery; MM=medical
management; PCI=percutaneous coronary intervention
Table 2 | Six year clinical outcomes by appropriateness category and actualmanagement. Values are numbers (percentages) unless stated otherwise
Appropriate for CABG only Appropriate for both Appropriate for PCI only
Received
CABG (n=408)
Received PCI
(n=54)
Received MM
(n=353)
Received
CABG (n=149)
Received PCI
(n=173)
Received MM
(n=198)
Received
CABG (n=45)
Received PCI
(n=137)
Received MM
(n=203)
Revascularisation 10 (2) 20 (37) 193 (55) 9 (6) 47 (27) 83 (42) 6 (13) 26 (19) 59 (29)
Chest pain admission 80 (20) 20 (37) 88 (25) 58 (39) 73 (42) 82 (41) 14 (31) 45 (33) 70 (34)
Non-fatal MI 19 (5) 2 (4) 23 (7) 15 (10) 19 (11) 16 (8) 3 (7) 7 (5) 10 (5)
Angina at 6 years: (n=238)100 (42) (n=34)27 (79) (n=195)99 (51) (n=89)52 (58) (n=102)61 (60) (n=119)82 (69) (n=26)11 (42) (n=95)49 (52) (n=122)79 (65)
Adjusted odds ratio*
(95% CI)
1 2.90
(1.03 to 8.14)
1.63
(1.09 to 2.42)
1 1.17
(0.69 to 1.98)
1.60
(0.89 to 2.87)
0.91
(0.39 to 2.13)
1 1.65
(0.95 to 2.87)
Deaths: 68 (17) 7 (13) 76 (22) 18 (12) 28 (16) 34 (17) 9 (20) 9 (7) 28 (14)
Adjusted hazard ratio*†
(95% CI)
1 0.58
(0.25 to 1.40)
1.41
(1.01 to 1.98)
1 2.00
(1.08 to 3.69)
1.70
(0.95 to 3.03)
2.10
(0.81 to 5.44)
1 1.33
(0.62 to 2.87)
CABG=coronary artery bypass graft; MI=myocardial infarction; MM=medical management; PCI=percutaneous coronary intervention.
*Adjusted for age, sex, ethnic group, Canadian Cardiovascular Society score, left ventricular function, previous stroke, MI, previous CABG, previous PCI, diabetes, diffuse disease,
diseased vessels, heart failure, and Parsonnet score; for all adjusted analyses, missing data have been imputed by multiple imputation23 and results are a summary of those from five
imputation datasets.24
†Overall hazard ratio presented despite some evidence of non-proportional hazards over time.
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of “extended dominance”—at any cost effectiveness
threshold, either medical management or bypass sur-
gery was amore cost effective option (fig 2). The incre-
mental cost effectiveness ratio for bypass surgery
compared with medical management was estimated as
£19 000 per quality adjusted life year (table 3). The
probability that bypass surgery, percutaneousmanage-
ment, and medical management are the most cost
effective forms of management was estimated at 63%,
22%, and 15% respectively (fig 2).
Among patients appropriate for percutaneous man-
agement only, percutaneous management dominated
bypass surgery (that is, it was less costly andmore effec-
tive than bypass surgery) and had an estimated incre-
mental cost effectiveness ratio of £47 000 per quality
adjusted life year comparedwithmedicalmanagement
(table 3). This incremental cost effectiveness ratio is
above the maximum usually considered acceptable
by the NHS, making medical management the most
cost effective treatment strategy in patients rated as
appropriate for percutaneous management. The prob-
ability that percutaneous management is most cost
effective was estimated at 36%, compared with 54%
for medical management (fig 2).
Sensitivity analysis
The cost effectiveness results were robust to adjust-
ment for the timing of the one year questionnaire, the
exclusion of patient reported cost data, and the inclu-
sion of other hospital admissions. Altering the defini-
tion of actual management to treatment received
within 15 months of angiography did not affect the
study results. However, among the group rated as
clinically appropriate for bypass surgery, altering the
definition of actual management to treatment received
within nine months caused the incremental cost effec-
tiveness ratio for bypass surgery comparedwith percu-
taneous management to increase from £22 000 to
£33 000.
DISCUSSION
Among consecutive patients, all of whom were judged
to be clinically appropriate for revascularisation, the
analysis suggests that bypass surgery within
12 months was cost effective in relation to a standard
UK threshold but that percutaneous management was
not. These findings challenge clinical practice and
healthcare policy, which has evolved on a basis of evi-
dence of effectiveness from clinical trials, largely in iso-
lation from considerations of cost effectiveness. As
angina pectoris has a high incidence and prognostic
burden in the general population,wheremany patients
are not evaluated for revascularisation,26 these findings
are important for public health.
Strengths and limitations
This study has several strengths. Firstly, we defined
clinical appropriateness by using an explicit method
that has been shown to be highly reliable and prognos-
tically valid.5 27 We used an expert panel to provide an
independent measure of appropriateness, before
recruitment of patients. Based on all forms of evi-
dence—meta-analyses,28 29 trials, observational studies,
and clinical experience—the panel’s judgments aimed
to articulate clinical appropriateness, without consid-
eration of cost.
Table 3 | Effectiveness and economicmeasures by appropriateness category and actualmanagement. Values aremean (SD) unless stated otherwise
Appropriate for CABG only (n=815) Appropriate for both (n=520) Appropriate for PCI only (n=385)
Received CABG
(n=408)
Received PCI
(n=54)
Received MM
(n=353)
Received CABG
(n=149)
Received PCI
(n=173)
Received MM
(n=198)
Received CABG
(n=45)
Received PCI
(n=137)
Received MM
(n=203)
Utility at
baseline*
(n=281)
0.54 (0.23)
(n=35)
0.48 (0.22)
(n=262)
0.60 (0.22)
(n=94)
0.45 (0.22)
(n=120)
0.50 (0.22)
(n=145)
0.54 (0.22)
(n=33)
0.56 (0.24)
(n=96)
0.57 (0.23)
(n=148)
0.61 (0.21)
Utility at 6 years* (n=264)
0.69 (0.29)
(n=35)
0.61 (0.36)
(n=219)
0.67 (0.31)
(n=100)
0.66 (0.31)
(n=108)
0.65 (0.30)
(n=131)
0.61 (0.30)
(n=28)
0.69 (0.28)
(n=100)
0.65 (0.29)
(n=129)
0.66 (0.29)
Life years†: 4.95 (1.47) 4.95 (1.57) 4.94 ( 1.32) 5.14 (1.19) 5.07 (1.27) 5.08 (1.14) 5.07 (1.15) 5.31 (0.95) 5.20 (0.95)
Adjusted MD
(95% CI)
0‡ 0.03
(−0.32 to 0.39)
−0.03
(−0.21 to 0.15)
0‡ −0.17
(−0.45 to 0.11)
−0.09
(−0.36 to 0.17)
−0.13
(−0.55 to 0.29)
0‡ 0.06
(−0.21 to 0.33)
QALYs†: (n=317)
3.29 (1.55)
(n=40)
3.01 (1.54)
(n=293)
3.02 (1.53)
(n=114)
3.13 (1.37)
(n=127)
2.93 (1.65)
(n=164)
2.83 (1.39)
(n=40)
3.08 (1.59)
(n=111 )
3.31 (1.47)
(n=161)
3.15 (1.43)
Adjusted MD
(95% CI)
0‡ −0.15
(−0.51 to 0.20)
−0.40
(−0.58 to −0.22)
0‡ −0.24
(−0.52 to 0.04)
−0.39
(−0.70 to −0.09)
−0.07
(−0.50 to 0.37)
0‡ −0.06
(−0.36 to 0.24)
Total cost (£)†: 16 980 (7879) 13 875 (7815) 10 850 (7220) 17 859 (6940) 14 007 (10 453) 10 690 (7888) 16 541 (5571) 11 493 (6468) 8775 (7364)
Adjusted MD
(95% CI)
0‡ −3230 (−5417 to
−1044)
−5870 (−6961 to
−4779)
0‡ −3820 (−5510 to
−2130)
−7255 (−8875 to
−5636)
4947 (2359 to
7534)
0‡ −2847 (−4510 to
−1184)
ICERs (£perQALY)
(from adjusted
values)
22 000 (v PCI) 11 000 (vMM) – 19 000 (vMM) ED – D 47 000 (vMM) –
CABG=coronary artery bypass graft; PCI=percutaneous coronary intervention; D=dominated; ED=ruled out by extended dominance; ICER=incremental cost effectiveness ratio (cost per QALY
gained calculated in comparison with next relevant, less costly alternative)19; MD=mean difference; MM=medical management; QALY=quality adjusted life year.
*Includes values from prediction model as well as observed utility (for six year values only).
†Discounted at rate of 3.5% a year.
‡Reference category.
Adjustments are for age, sex, ethnic group, Canadian Cardiovascular Society score, left ventricular function, previous stroke, myocardial infarction, previous CABG, previous PCI, diabetes,
diffuse disease, diseased vessels, heart failure, and Parsonnet score; adjusted analysis of QALYs and total cost are from seemingly unrelated regression and include an additional
adjustment for baseline utility; for all analyses missing data have been imputed by multiple imputation23; results are a summary of those from five imputation datasets.24
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Secondly, more than 90% of unselected consecutive
patients were matched to an appropriateness rating,
allowing our results to represent a real world view of
cost effectiveness; patients selected into clinical trials
may not be representative of unselected patients in
terms of baseline severity of disease, health related
quality of life, use of resources, and prognosis.30 The
case fatality we observed in this population (approxi-
mately 3% a year) was comparable to that seen in large,
less selected, primary care populations.26 Our analysis
wasmade possible by the ubiquitous phenomenon that
not all patients in whom revascularisation is deemed
appropriate will actually receive it. We have shown
that clinical appropriateness ratings in a broad unse-
lected population accord with evidence of clinical
effectiveness from trials.
Thirdly, wewere able tomake comparisons between
three alternative management strategies that may
never be simultaneously investigated in cost effective-
ness analysis alongside randomised trials. This is both a
strength and limitation; observational studies may be
the only study design to answer the research question,
but they comeat a cost of confounding. Patientswhogo
on to receive bypass surgery may have been destined
to have better outcomes than thosewhodonot, and the
results may therefore be “confounded by indication.”
We sought to redress this both by design (patients who
are judged to be suitable candidates for revascularisa-
tion are by definition more similar than those who are
not) and by analysis (by using multivariate regression
analysis to adjust for the potential confounding effects
of baseline clinical and demographic characteristics).
A second limitation of our analysis, inherent in the
need for long term follow-up studies, is that we do not
knowwhether percutaneousmanagement judged clini-
cally appropriate according to the most recent criteria
remains not cost effective. Although this awaits empiri-
cal testing, several lines of evidence indicate that this
may be the case. The cost of the percutaneousmanage-
ment procedure has increased with drug eluting
stents,31 and percutaneous management remains asso-
ciated with higher costs resulting from subsequent
admission to hospital. Meanwhile, an increasing num-
berof drugs for secondarypreventionhavebeen shown
to improve outcomes in chronic coronary disease.
Association of clinical appropriateness with better
outcomes
Patients who had bypass surgery were least likely to
have angina present at six years. This confirms findings
from randomised trials,2-32 but in a broader, unselected
population. The treatment rated as clinically appropri-
ate corresponds with the greatest number of quality
adjusted life years, although this result was statistically
significant only for the comparisonofmedicalmanage-
ment with clinically appropriate bypass surgery.
Throughout the six year follow-up of this unselected
patient group, quality of life remained lower than
expected from age specific population norms. The
low utility scores, despite intervention, reflect the find-
ings of the bypass angioplasty revascularisation inves-
tigation (BARI) trial, in which anginawas also found to
have a substantial negative impact on quality of life.33
Lack of cost effectiveness of percutaneous coronary
intervention
Our analysis indicates that clinically appropriate percu-
taneous management within 12 months was not cost
effective. Despite the large increase in numbers of per-
cutaneous coronary intervention procedures seen in
many countries, we do not find this result surprising:
the high costs of percutaneous management and the
need for subsequentprocedures,33234 absenceofmortal-
ity benefit,35 and absence of a marked gain in quality of
life have all been separately reported in trials. Our con-
tribution is to estimate jointly the cost and outcome of
percutaneous management that is considered clinically
appropriate, in comparison with medical management
and bypass surgery. The use of percutaneous manage-
ment has increased rapidly, on the sole basis of clinical
criteria without consideration of the economic conse-
quences. As a result, the funds invested in percutaneous
management could potentially be invested inmore cost
effective treatments that would provide greater benefit
to NHS patients.
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Cost effectiveness of bypass surgery
Bypass surgery within 12 months was the most cost
effective strategy among patients rated as appropriate
to have bypass surgery if the maximum incremental
cost effectiveness ratio the NHS is willing to accept is
around £30 000 per quality adjusted life year. How-
ever, if we define actual management as treatment
received within nine months (which may be viewed
as short given a mean UK waiting time of 6.5 months
at the time of the study36) the incremental cost effec-
tiveness ratio just exceeds £30 000 per quality
adjusted life year. We found that the relative cost dif-
ferences between bypass surgery and percutaneous
management reduced over the follow-up period, but
the absolute difference remained significant at six
years. Medical management is consistently the least
costly form of management; the low treatment costs
are not fully offset by high admission rates or costs of
late procedures. Previous trials have indicated a
greater degree of “catch up.” The BARI trial showed
an increase in percutaneous management costs from
65% to 98% of bypass surgery costs after 12 years of
follow-up; most of the gain was in the first five years.33
Future work could extend the cost effectiveness
model over a lifetime horizon, in which interventions
with large “up-front” costs, such as bypass surgery,
may seem more cost effective. Willingness to pay
thresholds differ markedly across countries with the
greatest numbers of people with chronic coronary
disease—India, China, Russia, United States—and
similar study designs could be used to inform national
policies.
Conclusion
This cost effectiveness analysis in a real world setting
offers a challenge to physicians, providers, and payers
to show that the management of coronary disease cur-
rently offered, however clinically beneficial, is also cost
effective. This was the case for bypass surgery within
12 months, but not for percutaneous management, for
which the additional benefit was too small to justify the
additional cost over the consistently less costly strategy
of medical management.
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ABSTRACT
Objective: To demonstrate the application of a Bayesian
mixed treatment comparison (MTC) model to synthesize
data from clinical trials to inform decisions based on all rel-
evant evidence.
Methods: The value of an MTC model is demonstrated
using a probabilistic decision-analytic model developed to
assess the cost-effectiveness of second-line chemotherapy in
ovarian cancer. Three clinical trials were found that each
made a different pair-wise comparison of three treatments of
interest in the overall patient population. As no common
comparator existed between the three trials, an MTC model
was used to assess the combined weight of evidence on sur-
vival from all three trials simultaneously. This analysis was
compared  to  an  alternative  approach  that  combined  two
of the trials to make the same comparison of all three treat-
ments using a common comparator, and an informal
approach that did not synthesize the available evidence.
Results: By including all three trials using an MTC model,
the credible intervals around estimated overall survival
were reduced compared with making the same comparison
using only two trials and a common comparator. Neverthe-
less, the survival estimates from the MTC model result in
greater uncertainty around the optimal treatment strategy
at a cost-effectiveness threshold of £30,000 per quality-
adjusted life-year.
Conclusions: MTC models can be used to combine more
data than would typically be included in a traditional meta-
analysis that relies on a common comparator. They can for-
mally quantify the combined uncertainty from all available
evidence, and can be conducted using the same analytical
approaches as standard meta-analyses.
Keywords: Bayesian, cost-effectiveness, evidence synthesis.
Introduction
Economic evaluation of health-care technologies is
increasingly recommended for informing allocation of
health-care resources in several countries around the
world [1]. For each disease area under consideration,
there may exist several competing, mutually exclusive
treatment  options.  A  decision  that  recommends  one
or more of these treatments as preferable to the rest
should be based on a simultaneous comparison of all
the relevant alternatives. Where this decision is made
on grounds of cost-effectiveness, the comparison needs
to produce a cardinal ranking of the alternatives. In
such cases, informal approaches that produce an ordi-
nal ranking of the alternatives will be insufficient. For
almost every set of technologies considered, it will be
necessary to combine information on costs and effects
from several sources, and modeling techniques will
invariably be employed. To aid decision-makers, deci-
sion modeling should be conducted within a clear ana-
lytical framework that is consistent, transparent and
able to take account of all available evidence.
A common feature of models comparing three or
more treatment options is the existence of several clin-
ical trials that each compare a different combination of
the relevant comparators. This network of evidence
requires that the analyst use methods of evidence syn-
thesis to derive the relative treatment effects of the
relevant comparators in a systematic and explicit
framework. There are many examples in the literature
of meta-analyses that synthesize trials comparing var-
ious treatments relative to a common comparator,
often placebo. Nevertheless, some networks may not
feature a common comparator between all trials, par-
ticularly where trials compare treatments to an active
control. This article presents an application of a mixed
treatment comparison (MTC) model to synthesize
three different pair-wise comparisons of three treat-
ments of interest [2,3], and discusses why this is the
most appropriate method of synthesizing these types of
data.
These methods were applied as part of a Technol-
ogy Assessment Report (TAR) for the National Insti-
tute for Health and Clinical Excellence (NICE) in the
UK. The process of decision analytic modeling is now
Griffin et al.124
seen as central to the process of health technology
assessment in general, and it plays a key role in the
NICE appraisal process [4]. To inform treatment deci-
sions for advanced second-line ovarian cancer, two
previous TARs had separately examined the cost-effec-
tiveness of topotecan and pegylated liposomal doxo-
rubicin hydrochloride (PLDH) [5,6]. An update was
commissioned because the previous assessments did
not provide the simultaneous direct comparison of
topotecan, paclitaxel and PLDH necessary to inform
the decision.
This article explores alternative approaches to esti-
mating the relative effectiveness of topotecan, paclit-
axel and PLDH for input into a cost-effectiveness
analysis. First we discuss the problems with an infor-
mal “naive” approach to the simultaneous comparison
before applying two different formal approaches. The
first formal approach is based on comparing relative
treatment effects to a common comparator. This
approach employs direct evidence on treatments where
they are compared with a common comparator, and
infers indirect comparisons between uncommon treat-
ments from different trials. The second formal
approach is based on an MTC model for combining
direct and indirect evidence simultaneously, and does
not require a common comparator between all trials.
Nevertheless, this approach does rely on the network
being “complete,” that is, that every trial have a treat-
ment in common with at least one other trial. Both
approaches were undertaken in the same software
platform to provide consistency in the methods of
calculation.
Methods
Overview
Existing studies provided only minimal assistance for
decision makers concerned with the reimbursement of
alternative chemotherapeutic agents [7,8], because no
simultaneous comparison of the three drugs had been
made. A new decision analytic model was therefore
developed to address this issue to provide information
for the relevant decision-maker (NICE). A full techni-
cal report is available relating to this work [9]; this
article focuses on the methodological issues related to
different approaches for synthesizing clinical data and
the key results for the overall patient population. The
objective is to highlight the importance of ensuring
that appropriate techniques are applied to the param-
eterization of decision models to characterize uncer-
tainty based on all relevant evidence. The model
estimates costs from a UK National Health Service
(NHS) perspective and health outcomes in terms of
life-years gained (LYG) and quality-adjusted life-years
(QALYs) for the full range of relevant treatment strat-
egies. An overview of the basic structure of the model
is provided in Figure 1. The uncertainty around the
utility weights and estimated resource use or costs
was characterized using appropriate probability
distributions.
The model calculates overall survival as the sum of
two distinct periods: the progression-free period, and
the time from progression to death, calculated as the
difference between overall survival and progression-
free survival (PFS). To calculate QALYs, overall sur-
vival is quality-adjusted using separate utility weights
for the two periods of time during which the average
patient is stable (i.e., progression-free) or in progres-
sion. The costs included relate only to the treatment
period and comprised the costs of study drugs, pre-
medication, monitoring, drug administration and the
cost of managing adverse events.
Progression-Free and Overall Survival
A systematic review was conducted to identify rand-
omized controlled trials (RCTs) and systematic reviews
comparing the clinical effectiveness of licensed chem-
otherapies (PLDH, topotecan and paclitaxel) with any
other second-line treatment, including best supportive
care. A total of nine RCTs were identified [10–18].
Four of these studies were excluded from the model
because the comparator groups (all unlicensed treat-
ments, either in terms of indication, dosage, and route
of administration or length of the chemotherapy cycle)
provided no evidence on the relationship between the
licensed treatments examined in this study [13–16].
The unlicensed comparator in each of these four trials
was uniquely represented, meaning the separate pair-
wise comparisons could not be linked to provide indi-
rect evidence about the relative treatment effects of
licensed comparators. The remaining five trials
assessed comparators that were used within their
licensed indications. Of the five included studies, three
included patients from the overall patient population
[10–12], and two included only participants with plat-
inum sensitive disease (relapse greater than 6 months
after first-line therapy) [17,18]. In the TAR for NICE
we considered all five trials and examined cost-effec-
tiveness in different subgroups. Nevertheless, for the
purpose of this article we focus on the three studies
that examined the overall patient population, to dem-
onstrate the methods for evidence synthesis. Table 1
shows the comparisons made in these three trials.
Figure 1 Structure of the economic model. Key: mean_surv = mean
(overall) survival time; mean_ttp = mean time to progression.
mean_surv
mean_ttp                         (mean_surv 
- mean_ttp) 
Stable
Disease
Progressive
Disease Dead
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No trial compared all the relevant treatment com-
parators simultaneously and there are three different
pair-wise comparisons of the relevant comparators in
the three included studies in the overall patient popu-
lation. The first step in reviewing the available evi-
dence was to examine the characteristics of each trial
and the data reported. All trials were conducted in
comparable patient populations with similar inclusion
and exclusion criteria. The main distinction between
the trials was the length of follow-up. Trial A had a
median follow-up of approximately 3 years; trial B
had a median follow-up of approximately 4 years; trial
C did not report median follow-up, but the maximum
follow-up was approximately 3 years, so we may infer
that the median follow-up was less than 3 years. Sur-
vival data were presented as median weeks overall and
PFS and in the form of hazard ratios between treat-
ments. The hazard ratio represents the most accurate
of these measures for comparing survival between
treatments, because it is specifically designed to allow
for censoring and time to an event [19]. Furthermore,
the use of the (log) hazard ratio and its variance allows
studies to be pooled using conventional meta-analytic
approaches. Trial C [12] provided data on overall sur-
vival, but not PFS.
Table 2  presents the hazard ratios for overall sur-
vival and PFS extracted from the trials. It is clear that
the three trials provide inconsistent information on the
relative effectiveness of the three comparators. The
results from trial A would suggest that topotecan is
superior to paclitaxel, and the results from trial B sug-
gest that PLDH is superior to topotecan. This would
lead one to infer that PLDH would appear superior to
paclitaxel in trial C, but this is not the case. Trials A
and C were smaller than trial B, and this incongruous
result could be put down to random chance. In this
sense one may expect some inconsistency in most net-
works of evidence, although perhaps not as evident as
in this example. Another factor to consider is the dif-
fering lengths of follow-up and what impact we may
expect this to have on the hazard ratios. As each clin-
ical trial estimated the hazard ratio using a Cox pro-
portional hazards model [20], some assumption about
the independence of the hazard ratio with respect to
time has already been made. We similarly assumed that
the hazard ratio was independent of length of follow-
up, and thus the two formal approaches are based on
the assumption that the hazard ratios estimated in the
included trials are exchangeable.
Methods for Evidence Synthesis
A simple, informal approach to this network of evi-
dence might be to make inferences based only on the
direct comparisons made within each trial. For exam-
ple, one might present three separate “pair-wise” anal-
yses (PLDH vs. topotecan, topotecan vs. paclitaxel and
PLDH vs. paclitaxel) based on the results of each indi-
vidual trial. Nevertheless, clearly this approach does
not fulfill the objective of providing a simultaneous
direct comparison of all the relevant alternatives, and
cannot produce a cardinal ranking of the alternatives
or provide information about the associated decision
uncertainty. Hence, for the purposes of decision-
making, this approach does not provide an appropri-
ate analytic framework.
An alternative, more formal approach, that is com-
monly applied, is to compare the relevant treatments
on the basis of a common comparator [21]. In this
example, because there is no single comparator which
is common to each of the studies, only two of the three
trials could be included at any one time. For example,
if topotecan were selected as a common baseline, one
could perform a cost-effectiveness analysis of all three
treatments on the basis of the hazard ratios reported in
trials A and B, to the exclusion of the information pro-
vided by trial C. Although this approach has certain
advantages in comparison to the informal approach
(i.e., it can provide a cardinal ranking and associated
decision uncertainty), it also has a number of impor-
tant limitations. Most importantly, by considering
only two of the three trials, this approach makes selec-
tive use of the relevant evidence-base and, in doing so,
ignores the information provided in the trial which has
been omitted. Depending on the results of the omitted
study, its exclusion could have important conse-
Table 1 Comparisons made in the included trials
Trial PLDH Topotecan Paclitaxel
A* [10] ✓ ✓
B [11] ✓ ✓
C [12] ✓ ✓
*Update provided to NICE of previously published trial [34].
PLDH, pegylated liposomal doxorubicin hydrochloride.
Table 2 Hazard ratios extracted from included trials
Trial
Overall survival
Hazard ratio* (95% CI)
Progression-free survival
Hazard ratio* (95% CI)
A: Topotecan vs. Paclitaxel [11] 0.914 (0.681–1.226) 0.811 (0.603–1.092)
B: Topotecan vs. PLDH [10] 1.216 (1–1.478) 1.118 (0.928–1.347)
C: Paclitaxel vs. PLDH [12] 0.931 (0.702–1.234) n/a
*Hazard ratio less than one favors topotecan in trials A and B, and paclitaxel in trial C.
CI, confidence interval; n/a, not available; PLDH, pegylated liposomal doxorubicin hydrochloride.
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quences for both the incremental cost-effectiveness
ratio (ICER) and the associated decision uncertainty.
Consequently, in those situations where there is no
common comparator across all relevant trials, this
approach does not provide an appropriate framework
for decision making which is able to take account of all
relevant evidence.
It is possible to incorporate all this evidence simul-
taneously in the form of an MTC model [2,3]. Such a
model provides an explicit analytical framework to
identify the most cost-effective treatment strategy
given the combined weight of evidence from all the rel-
evant clinical trials. There are several examples in the
literature of statistical models for combining mixed
comparison evidence to provide a consistent set of
treatment effect estimates, relative to a common base-
line [22]. Using a similar approach, a model was devel-
oped to estimate a set of hazard ratios relative to a
common baseline, using the Bayesian inference soft-
ware program WinBUGS [23]. One of the advantages
of a Bayesian approach is the ability to make explicit
probability statements about hypotheses, for example,
the probability that a particular strategy is the most
cost-effective alternative.
To correctly incorporate data from every trial, a
Bayesian MTC model, assuming fixed treatment
effects, was used to combine the (log) hazard ratios [2].
In brief, the technique extends the assumptions made
in simple meta-analyses to include the principle of
transitivity: if the true differences between three pair-
wise comparisons of treatments X, Y, and Z are θXY,
θXZ, and θYZ, then we expect:
θXZ = θXY + θYZ (1)
An additional assumption is that treatment effects can
be expressed on an appropriate scale, such as log haz-
ard ratio. The analyst must decide whether the patient
populations and other trial characteristics are homog-
enous enough to justify synthesizing the relative treat-
ment effects across the trials. The variances around the
reported hazard ratios were used to incorporate the
uncertainty around the estimated treatment effects.
The analysis assumes that the (log) hazard ratios,
observed in the clinical trials, are normally distributed
about a true underlying effect size, θ, according to the
precision (= 1/variance), τ2, also observed in the trials.
The underlying treatment effects are given independent
vague priors, N (0, 0.001). The term “vague” is used
to denote that prior information in the form of expert
opinion or prior data is not included in the analysis,
and hence these parameters are assigned very diffuse
distributions. In other examples where prior informa-
tion is available, this can be translated into informative
priors for the relevant model parameters. The main
premise of the analysis is that had paclitaxel been
included as a comparator in trial A, or PLDH included
as a comparator in trial B, the observed relative treat-
ment effect of paclitaxel compared with PLDH would
have been the same as that observed in trial C.
Log(HRtop_pac) ∼ N(θtop_pac,τ2top_pac);
θtop_pac ∼ N(0,0.001) (2)
Log(HRtop_PLDH) ∼ N(θtop_PLDH,τ2top_PLDH);
θtop_PLDH ∼ N(0,0.001) (3)
Log(HRpac_PLDH) ∼ N(θpac_PLDH, τ2pac_PLDH);
θpac_PLDH = θtop_PLDH − θtop_pac (4)
Where top_pac = topotecan vs. paclitaxel; top_PLDH
= topotecan vs. PLDH; pac_PLDH = paclitaxel vs.
PLDH. The full WinBUGS code for the evidence syn-
thesis is available elsewhere [9].
Cost-Effectiveness Analysis
The advantages of the MTC model in comparison to
the other approaches are examined in detail by under-
taking separate cost-effectiveness analyses using the
different methods. The hazard ratios from each
approach are used to calculate expected costs and
QALYs, using the same probabilistic decision-analytic
model. The following sections describe in more detail
how the hazard ratios were used in calculating mean
quality-adjusted survival.
Absolute PFS and overall survival were calculated
for a specified baseline regimen to apply the estimated
hazard ratios for the other two regimes. An active
treatment was chosen to represent the baseline regimen
because no trial provided a comparison with support-
ive care (no chemotherapy). Topotecan was selected as
the baseline comparator for the formal approaches,
because trial data for topotecan were presented over
the longest period of follow-up (approximately
4 years), and in the greatest detail. For the informal
approach of three separate pair-wise comparisons,
paclitaxel was used as the baseline in the trial that did
not include topotecan. None of the trials provided an
estimate of the absolute hazard of progression or death
for an individual treatment, and so an exponential
approximation was used to calculate the absolute
hazards from the reported median PFS and overall
survival. The baseline absolute hazard (h) and its
variance was calculated according to the following
formulae:
h = − LN(0.5)/t (5)
Var (h) = h2/r (6)
Where t = median weeks survival; r = number of
events.
Using this approach, the baseline absolute hazard
(h) can then be converted into a mean survival time,
for PFS and overall survival, by simply taking the
inverse of the hazard (1/h). This conversion from
median to mean survival is necessary, because the deci-
sion about whether an intervention is cost-effective is
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made on the basis of the expected costs and effects at
the population level [24]. Because survival data typi-
cally follow a skewed (i.e., not symmetrical) distribu-
tion, the  median  does  not  provide  a  good  estimate
of the mean. The estimated hazard ratios were then
applied to the baseline absolute hazard to calculate the
absolute hazard of progression and death for paclit-
axel and PLDH. These were also converted into mean
PFS and overall survival by taking the inverse of the
absolute hazard.
Table 3  shows the WinBUGS code used to under-
take the two different formal approaches to calculating
the relative treatment effects for overall survival. Sim-
ilar models were used to estimate PFS and the rate of
adverse events. When basing the analysis on direct
comparisons against topotecan, trial C is excluded.
The MTC model allows the information from trial C
to be incorporated, based on the assumptions outlined
above. Each model was run for 20,000 iterations, from
which the data from the first 10,000 were discarded to
allow the model to “burn-in” or converge. Ten thou-
sand iterations were used to ensure full coverage of the
distribution of incremental net benefits in the proba-
bilistic sensitivity analysis.
The output from the meta-analyses undertaken in
WinBUGS was imported directly into Microsoft Excel
2000. This output consisted of 10,000 draws from the
posterior distributions for PFS and overall survival
(and adverse events) for each drug. These data incor-
porate the uncertainty around expected survival. The
survival estimates were then combined with data on
resource use and cost to obtain the mean estimates for
the outcomes of interest and their associated uncer-
tainty. Given that mean costs and QALYs gained are
estimated with uncertainty, the outputs from the sim-
ulations were then used to generate cost-effectiveness
acceptability curves (CEACs) for the alternative anal-
yses [25]. These show the probability that each strat-
egy is the most cost-effective given alternative
maximum values that the health service may be willing
to pay for an additional QALY. Previous studies have
estimated the threshold for cost-effectiveness to be in
the range of £20,000 to £40,000 per QALY in the UK
NHS [26].
Results
Using the model structure developed for the assess-
ment report [9], a cost-effectiveness analysis based
solely on trial A would conclude that PLDH dominates
topotecan, because it is estimated to be the more effec-
tive and cheaper alternative. A cost-effectiveness anal-
ysis based solely on trial B would produce an ICER of
£33,532 per QALY gained with topotecan compared
with paclitaxel. A cost-effectiveness analysis based
solely on trial C would not be able to estimate QALYs
because of the lack of data on PFS; one may wish to
infer that paclitaxel would dominate PLDH, on the
Table 3 WinBUGS code for estimating treatments effects based on a common comparator, and using an MTC model
Common comparator MTC model
model { model {
# priors for basic parameters # priors for basic parameters
dab ~ dnorm(0.001) #LHR a vs. b dab ~ dnorm(0, 0.001) #LHR a vs. b
dac ~ dnorm(0.001) # LHR a vs. c dac ~ dnorm(0, 0.001) # LHR a vs. c
la ~ dnorm(0.001) # Log hazard rate for a la ~ dnorm(0, 0.001) # Log hazard rate for a
# define functional parameters
dbc <- dac - dab
# define absolute hazards on log scale # define absolute hazards on log scale
ltopo ~ dnorm(la,ptopo) ltopo ~ dnorm(la,ptopo)
lb <- la - dab lb <- la - dab
lc <- la - dac lc <- la - dac
# define absolute hazards natural scale # define absolute hazards natural scale
log(a) <- la log(a) <- la
log(b) <- lb log(b) <- lb
log(c) <- lc log(c) <- lc
# convert to mean survival # convert to mean survival
OSa <- 1/a OSa <- 1/a
OSb <- 1/b OSb <- 1/b
OSc <- 1/c OSc <- 1/c
# likelihood # likelihood
yab ~ dnorm(dab,pab) yab ~ dnorm(dab,pab)
yac ~ dnorm(dac,pac) yac ~ dnorm(dac,pac)
} ybc ~ dnorm(dbc,pbc)
}
# data list (log hazard ratios, precision, baseline hazard and precision) # data list (log hazard ratios, precision, baseline hazard and precision)
list(yab = -0.0899,yac = 0.1956, pab = 44.4520,pac = 100.6718, 
ltopo = -4.4558, ptopo = 114.9304)
list(yab = -0.0899,yac = 0.1956,ybc = -0.0715, pab = 44.4520, 
pac = 100.6718,pbc = 48.2933, ltopo = -4.4558, 
ptopo = 114.9304)
MTC, mixed treatment comparison. Text in bold is the actual Winbugs code. Text not in bold is annotation of the Winbugs code.
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basis of survival, but this would be both inconsistent
and inferior to the analyses of trials A and B based on
cost per QALY [27]. This informal approach clearly
cannot inform a decision between all relevant compa-
rators because it does not reconcile the information
provided by the three trials in a coherent analytical
framework.
Table 4 presents the log hazard ratios for overall
survival and their associated 95% credible intervals
from the two formal analyses. It also displays the
results from the decision-analytic model based on each
set of hazard ratios. Despite the introduction of poten-
tially inconsistent evidence from trial C, the 95% cred-
ible intervals from the MTC model are marginally
smaller compared with the model that excludes trial C.
The data from trial C reduce the amount by which
PLDH is estimated to be superior to paclitaxel,
although the direction of effect does not change. What
does change is the direction of effect for topotecan vs.
paclitaxel, which is reversed in the analysis using the
MTC model to incorporate information from all three
trials. Although this results in topotecan being domi-
nated by paclitaxel in the decision-analytic model,
qualitatively the adoption decision is unaffected; if we
assume that society is willing to pay more than
£17,000 for an additional QALY PLDH is found to be
the optimal treatment strategy in both analyses.
Figure 2 shows the CEACs for the two analyses. The
reduction in the amount by which PLDH is estimated
to be superior to paclitaxel increases the uncertainty in
the adoption decision for cost-effectiveness thresholds
in the range of £20,000 to £40,000 per QALY.
The indirect hazard ratio for paclitaxel compared
with PLDH from the approach that excludes trial C is
1.33 (e0.288). If we compare this to the direct compar-
ison of these drugs in trial C, shown in Table 1, we see
that this is outside the range of the 95% confidence
interval reported in the trial. The hazard ratios from
the MTC model all lie within the 95% confidence
intervals of the direct comparisons reported in the clin-
ical trials.
Discussion
If no attempt is made to synthesize data from multiple
clinical trials, a set of individual trial-based cost-effec-
tiveness analyses will be insufficient to inform a deci-
sion that must recommend one or more optimal
strategies among all relevant alternatives. In this exam-
ple, the inconsistency between the trial estimates in iso-
lation meant that the series of pair-wise comparisons
provided conflicting evidence. Nevertheless, this prob-
lem occurs even without conflicting evidence. Consider
two pair-wise comparisons based on trials A (PLDH
vs. topotecan) and B (topotecan vs. paclitaxel). PLDH
dominates topotecan in trial A, and so we may wish to
compare it to paclitaxel in an incremental analysis.
Nevertheless, the costs and effects of paclitaxel have
been estimated against a different topotecan baseline
compared with PLDH, and so calculating the ICER
from the two separate trial-based analyses would be
incorrect. Added to that is the inability of this
approach to inform decision makers adequately about
uncertainty. The limitations of the “naive” approach
are evident even in this very simple example. Clearly,
as the number of relevant trials and comparisons
increases, so too will the difficulty of reconciling the
information provided by a list of inconsistent, dispa-
rate pair-wise comparisons.
When faced with a network of evidence that does
not feature a common comparator among all the tri-
als, more traditional methods of meta-analysis could
not make use of all the available data [28–30]. The
choice of common comparator, and therefore the
choice  of  which  studies  to  exclude,  would  affect
the results of the analysis. In this example we chose
topotecan as the common baseline; however, the
results would have been completely different had we
chosen paclitaxel as the common comparator. The
exclusion of available data can lead to greater uncer-
tainty in estimated treatment effects, which will in turn
affect the decision uncertainty. If decision makers are
also responsible for issuing recommendations about
Table 4 Results from the WinBUGS model and decision-analytic model based on using a common comparator, and using an MTC
model
Common comparator MTC model
WinBUGS output Log hazard ratio for overall survival Log hazard ratio for overall survival
(95% credible interval) (95% credible interval)
Topotecan vs. paclitaxel −0.092 (−0.390 to 0.206) 0.060 (−0.162 to 0.287)
Topotecan vs. PLDH 0.196 (0.001 to 0.389) 0.129 (−0.046 to 0.304)
Paclitaxel vs. PLDH Implied 0.288 (−0.0641 to 0.646) 0.069 (−0.153 to 0.294)
Cost-effectiveness Topotecan Paclitaxel PLDH Topotecan Paclitaxel PLDH
Mean PFS (weeks) 24.50 20.13 27.49 24.50 20.13 27.49
Mean OS (weeks) 86.03 79.70 104.79 86.03 92.06 98.08
Quality-adjusted survival (weeks) 34.21 30.86 40.91 34.21 34.63 38.86
Total cost (£) 11,394 6,354 7,714 11,394 6,354 7,714
ICER D — 7,033 D — 16,714
D, dominated; ICER, incremental cost-effectiveness ratio in terms of cost per quality-adjusted life-year; MTC, mixed treatment comparison; OS, overall survival.
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further research, the decision to do so is likely to be a
function of the decision uncertainty, which can be for-
mally represented using value of information analysis
[31–33]. If the value of collecting more information on
any model parameter exceeds the costs of collecting
that information, a gain can be made from instigating
the necessary research. The failure to incorporate data
that are already available may lead to erroneous rec-
ommendations. Because of the inconsistent nature of
the available evidence in this example, the indirect
hazard ratio estimated for paclitaxel compared with
PLDH, when using topotecan as a common compara-
tor, is actually outside of the 95% confidence interval
reported from the direct head-to-head comparison in
trial C. This demonstrates, to some extent, the
strength of the assumption to exclude available data.
In other words, this approach assumes that trial C
contributes no information at all to the paclitaxel vs.
PLDH comparison.
An MTC model provides an analytic framework to
incorporate evidence in situations where there exists
both direct head-to-head evidence and indirect evi-
dence relative to a common comparator. Clearly when
indirect evidence is used to estimate treatment effects it
is not possible to rule out the introduction of bias, and
the results should be interpreted accordingly, as they
should for any meta-analysis. The validity of the result
is dependent on the assumption that the relative treat-
ment effects would be equal were they observed in any
of the included trials. In this example, the three trials
provide inconsistent evidence as to the relative effec-
tiveness of the three comparators. Although this may
be the product of random chance, particularly where
trials are small, it is important to consider whether
there is a systematic explanation for the inconsistency.
In this example the length of follow-up differs between
the trials. If the hazard ratio for overall survival varies
with the length of follow-up, then it would be inap-
propriate to synthesize the hazard ratios from all three
trials on the basis that they were directly exchangeable.
This also applies to the approach where two trials were
combined based on a common comparator. The Baye-
sian nature of the MTC model would allow the incor-
poration of prior information about the expected
change in hazard ratio over time; however, none was
available in this case. The MTC approach is, however,
based on only a few additional assumptions over
standard meta-analysis. It is a method to explicitly
incorporate indirect evidence and quantify its uncer-
tainty. The choice of which trials to synthesize must be
Figure 2 Cost-effectiveness acceptability
curves generated from decision-analytic model
using relative hazards calculated based on a
common comparator (topotecan), and using a
mixed treatment comparison (MTC) model.
PLDH,  pegylated  liposomal  doxorubicin
hydrochloride.
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made in both formal approaches demonstrated here,
with consideration of the trial characteristics and how
each can contribute to the decision problem.
In this example, the use of an MTC model margin-
ally reduced the uncertainty around the estimated
treatment effects by incorporating all the available evi-
dence. Nevertheless, it also reduced the amount by
which the optimal treatment strategy was estimated to
be superior to the next best alternative. This did not
affect the adoption decision based on current evidence
if we assume that society is willing to pay more than
£17,000 per additional QALY, but it did increase the
uncertainty in the adoption decision for the range of
values of cost-effectiveness threshold commonly used
in the UK. This ability of additional information to
change the point estimates of relative treatment effects,
at the same time as reducing the uncertainty around
them, means that incorporating all available evidence
could affect the uncertainty around the adoption deci-
sion in either direction. Thus, the effect of omitting
some of the available evidence cannot be informally
predicted.
If executed with the same analytical rigor as stand-
ard meta-analyses, MTC models provide a robust
method for formally synthesizing both direct and indi-
rect evidence to calculate the expected value and asso-
ciated uncertainty around treatment effects and other
parameters for input into decision-analytic models.
This can only further improve on the assistance deci-
sion-analytic models provide to decision makers who
wish to rank competing alternatives in terms of cost-
effectiveness and assess the associated decision
uncertainty.
Source of financial support: This project was funded by the
Health Technology Assessment Programme (project number
04/03/01) and commissioned on behalf of NICE. The views
expressed are those of the authors and do not necessarily
reflect those of the Department of Health. 
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ABSTRACT
 
Objective:
 
To assess the importance of considering decision
uncertainty, the appropriateness of probabilistic sensitivity
analysis (PSA), and the use of patient-level simulation (PLS)
in appraisals for the National Institute for Health and Clin-
ical Excellence (NICE).
 
Methods:
 
Decision-makers require estimates of decision
uncertainty alongside expected net benefits (NB) of interven-
tions. This requirement may be difficult in computationally
expensive models, for example, those employing PLS. NICE
appraisals published up until January 2005 were reviewed to
identify those where the assessment group utilized a PLS
model structure to estimate NB. After identifying PLS mod-
els, all appraisals published in the same year were reviewed.
 
Results:
 
Among models using PLS, one out of six conducted
PSA, compared with 16 out of 24 cohort models. Justifica-
tion for omitting PSA was absent in most cases. Reasons for
choosing PLS included treatment switching, sampling patient
characteristics and dependence on patient history. Alterna-
tive modeling approaches exist to handle these, including
semi-Markov models and emulators that eliminate the need
for two-level simulation. Stochastic treatment switching and
sampling baseline characteristics do not inform adoption
decisions. Modeling patient history does not necessitate PLS,
and can depend on the software used. PLS addresses nonlin-
ear relationships between patient variability and model out-
puts, but other options exist. Increased computing power,
emulators or closed-form approximations can facilitate PSA
in computationally expensive models.
 
Conclusions:
 
In developing models analysts should consider
the dual requirement of estimating expected NB and charac-
terizing decision uncertainty. It is possible to develop models
that meet these requirements within the constraints set by
decision-makers.
 
Keywords:
 
 cost-effectiveness analysis, decision uncertainty,
decision-analytic modeling, patient-level simulation, proba-
bilistic analysis.
 
Introduction
 
Economic evaluation of health-care technologies is
increasingly recommended internationally for inform-
ing the allocation of health-care resources [1]. For
almost every set of technologies considered, it will be
necessary to combine information on costs and effects
from several sources, and modeling techniques will be
employed. When building any decision model, it is
important to consider how to handle uncertainty and
variability, because these affect the value and interpre-
tation of the model output. Decision-makers require
unbiased estimates of the costs and effects of alterna-
tive interventions for identifiable patient groups, and
the ability of a model structure to provide these can
depend on how uncertainty, variability, and heteroge-
neity are handled in the structure. There is also a need
to provide an assessment of whether current evidence
is sufficient to support the decision to adopt a technol-
ogy. By formally estimating decision uncertainty, the
value of obtaining additional information on model
parameters can be assessed [2–4].
In this article we explore methods available to
address uncertainty, variability, and heterogeneity
within decision models. We explore how the current
methods for conducting probabilistic sensitivity anal-
ysis (PSA) to characterize decision uncertainty can con-
flict with the use of computationally expensive model
structures. The premise is that the purpose of a
decision model is to provide unbiased estimates of
expected cost and effects, and of decision uncertainty,
in a timely fashion and within resource constraints as
determined by the decision-maker that commissions
the model. In this article, the focus is on one particular
decision-maker, the National Institute for Health and
Clinical Excellence (NICE) in the UK. This focus has a
number of advantages: 1) NICE is an agency with a
history of using decision-analytic cost-effectiveness
models as a basis for deciding whether to support the
use of particular health-care technologies in the UK
National Health Service (NHS) [5]; 2) by focusing on
a single decision-maker, the case studies identified in
the review will have been developed with consistent
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time and resource constraints; 3) NICE has specified a
reference case that defines those methods considered
most appropriate for informing decisions about the
adoption of new technologies [6], which makes the
case studies identified in the review comparable in this
respect; and 4) the potential conflict between PSA and
computationally expensive model structures is perti-
nent, because the reference case now calls for the use of
PSA as the appropriate way by which the combined
implications of uncertainty in all model parameters be
reflected [7].
Although the review is specific to NICE, issues
relating to the provision of unbiased estimates of costs
and effects and quantifying decision uncertainty, while
reflecting the complexity of the disease process and
treatment effect under time and resource constraints,
are more general and relevant to decision models
developed in different contexts.
 
Review Methods
 
The review allows an exploration of the potential con-
flict between the use of computationally expensive
model structures and the implementation of PSA in
models submitted to NICE. For the purposes of this
review, computational expense refers to the limited
resources available with which to produce model
results, given the constraints of the decision-making
process. Models may be computationally expensive for
a number of reasons. For our review, the use of
patient-level simulation (PLS) was selected as an indi-
cator of computational expense because its use should
be readily apparent in models submitted to NICE and,
for a given model structure, analysis using PLS is more
computationally expensive than a cohort analysis.
All technology appraisals detailed on the NICE
Web site that were published up until January 2005
were reviewed to identify those where the independ-
ent technology assessment group had utilized a model
structure involving PLS to provide an estimate of
cost-effectiveness. After identifying models that
employed PLS, appraisals published in the same year
were identified and reviewed. The benefit of compar-
ing models that employed PLS with models published
in the same period is the consistency of constraints
facing model developers. Given the computing
expense of PSA, it might be expected that it would be
more common among models employing a cohort
framework. We identified common stated reasons for
choosing a PLS rather than a cohort framework, and
assessed their implications for model structure with
respect to uncertainty, variability, and heterogeneity.
For each case study, we ascertained whether a PSA
had been undertaken. In cases where a PSA had not
been undertaken, we explored the availability of alter-
native modeling techniques, such as less computation-
ally expensive modeling structures or emulators. In
those cases where PSA was performed, we discuss the
techniques used.
 
Uncertainty, Variability, and Heterogeneity
 
In this section, we distinguish uncertainty, variability,
and  heterogeneity,  explore  the  implications  of  each
for model structure and interpretation of results, and
briefly review the methods available for characterizing
decision uncertainty.
 
Decision Uncertainty
 
Decision uncertainty can be regarded as epistemic
uncertainty [8] which relates to model parameters that
have a definite value, but which cannot be known with
certainty. For example, the risk of future individual
developing cervical cancer has a definite value, but one
which we can only estimate with uncertainty. This
uncertainty can be characterized with a distribution
and can be reduced with further investigation. Epis-
temic uncertainty is not confined to model parameters,
and may exist in the determination of model structure.
This discussion concentrates on parameter uncertainty,
although it can be generalized to other sources of
uncertainty [9].
The decision to adopt a particular technology
should be based on expected net benefit (NB) so that,
when comparing mutually exclusive treatment strate-
gies for a particular disease area, the optimal strategy
is simply the one with the highest expected NB [10].
Nevertheless, uncertainty is important for two reasons:
1) in nonlinear models, or multilinear models with cor-
related parameters, unbiased estimates of expected NB
require a characterization of uncertainty; and 2) deci-
sions based on expected NB are only appropriate if
there is also some consideration of whether current
evidence is sufficient for allocating health-care
resources, based on an assessment of the consequences
of decision uncertainty [11]. If the decision uncer-
tainty, and/or the consequences of adopting a subop-
timal treatment strategy are large, the decision-maker
may require further evidence on which to base the
adoption decision [4].
 
Variability
 
Expected costs and effects are not only uncertain but
also vary across individuals with identical observed
characteristics. This variability can be regarded as
aleatory uncertainty [8] which arises as a result of sto-
chastic variation. It cannot be reduced through meas-
urement, but can be characterized with empirical
distributions. For example, the rate at which an indi-
vidual’s cervical cancer develops will vary between
patients. We can describe the distribution of the rate of
cancer progression by counting the number of patients
who progress at different rates. Nevertheless, further
investigation would not reduce variation in the rate of
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progression. Another example is where, given a prob-
ability of an event occurring, such as death, the reali-
zation of that event can be imagined as being governed
by a lottery. So we may know with certainty that the
probability of death is, for example, 5%, but we do
not know which 5% of people will die.
Variability in itself is not relevant to an adoption
decision based on expected NB. Nevertheless, it may
be necessary to explicitly represent variability in model
structures to obtain an unbiased estimate of expected
NB if, within a patient population which is homoge-
neous in observed baseline characteristics, there is a
nonlinear relationship between a characteristic that
varies between patients and NB.
For example, suppose the outcome of interest, cost
(
 
C
 
), is a nonlinear function of some patient character-
istic (
 
x
 
) with mean, 
 
µ
 
, that varies between patients (i)
according to a normal distribution with variance 
 
σ
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The expected value of 
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 across all patients, E[
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], can-
not be used to derive the expected value of 
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; an esti-
mate of E[
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] is required because E[
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≠
 
 E[
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]. In this
instance, an analysis which failed to account for the
variability in 
 
x
 
 across patients would provide biased
estimates of expected costs. The use of PLS accounts
for  variability  in  all  included  parameters,  regardless
of whether there exist any nonlinear relationships
between these parameters and model output. Never-
theless, there are a number of other methods by which
we could also address this issue.
For example, by repeatedly sampling from 
 
µ
 
 and 
 
σ
 
we can estimate E[
 
x
 
i
2
 
] as an input to the model. Alter-
natively it may be possible to derive a linear approxi-
mation to the model. That is, we find a mathematical
function of 
 
µ
 
 and 
 
σ
 
 that gives us E[
 
x
 
i
2
 
], that is, deter-
mine function G such that:
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The requirement to account for variability in model
structure under these circumstances does not negate
the need to estimate decision uncertainty. Failure to
account for uncertainty will also lead to biased esti-
mates of cost and effect in a nonlinear model. Conse-
quently, under these circumstances, both variability
and uncertainty must be characterized in order prop-
erly to inform an adoption decision. In model struc-
tures which are linear with respect to variability but
nonlinear with respect to uncertainty, unbiased esti-
mates of NB require the characterization of uncer-
tainty but not variability. Where models are linear or
multilinear (with independent parameters), it is not
necessary to represent variability or uncertainty to
obtain unbiased estimates of expected NB. Neverthe-
less, it will still be necessary to represent uncertainty in
a model structure to address the question of whether
current evidence provides sufficient basis for the adop-
tion decision.
 
Heterogeneity
 
Heterogeneity can be regarded as variation as a result
of observed characteristics on which it is possible to
condition model parameters and therefore expected
NB. Such heterogeneity must be observable at the time
at which the treatment decision is taken. For example,
the risk of developing cervical cancer may depend on
family history. In principle, this can be observed and
subsequent decisions, such as the decision of whether
to screen, based on this observation. This contrasts
with variation in the rate of disease progression which
is unobservable at the time at which the decision to
screen is made. Thus, one could not decide to screen
only those patients whose cancer would develop at a
fast rate. When estimating the cost-effectiveness of an
intervention for a heterogeneous population, one can
condition on the observed characteristics and separate
the overall group into homogenous subpopulations
within which patients have identical observed charac-
teristics. The model can then be run separately for each
homogenous group to generate estimates of cost-
effectiveness conditional on each set of observed char-
acteristics. Adoption decisions can then made for each
of these mutually exclusive and identifiable patient
groups [12].
 
Probabilistic Sensitivity Analysis
 
In this section, we consider the role of PSA in dealing
with uncertainty in decision models. One- and multi-
way sensitivity analyses cannot reflect the combined
uncertainty in all model parameters, and so are inap-
propriate for informing decision uncertainty. PSA,
when conducted properly, provides a more rigorous
approach by requiring that all input parameters in a
model be specified as full probability distributions,
rather than as point estimates, to indicate the uncer-
tainty of the estimates [13]. PSA can be used accurately
to estimate expected NB in a nonlinear model, and also
to reveal the effect of the combined uncertainty in all
model parameters.
Decisions based on expectation are only appropri-
ate if the consequences of the uncertainty surrounding
the decision are also considered. This informs the nec-
essary question about whether current evidence is suf-
ficient or whether further research is needed. Formal
methods are available to estimate this value of infor-
mation [2] and these are now recommended, although
not required, by NICE. Nevertheless, for the purposes
of this review it is sufficient to note that an appropriate
characterization of decision uncertainty is a prerequi-
site for any assessment of the consequences of decision
uncertainty, whether or not this achieved using formal
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methods. Clearly, decisions based on point estimates
without any consideration of uncertainty will lead to
the adoption of technologies with inadequate and poor
quality evidence [3,10]. Therefore, adoption decisions
cannot be separated from an assessment of whether the
evidence is sufficient to support such decisions. For
example, as well as making the adoption decision,
NICE also makes recommendations for future
research, specifies a review date for guidance, in part
based on when new evidence is expected to be availa-
ble, and has issued guidance conditional on further
evidence being collected to inform future decisions.
 
Implementing PSA
 
PSA is commonly conducted using Monte Carlo sim-
ulation. The model is run repeatedly, and each run uses
new random draws from distributions describing the
uncertainty surrounding the value of each of the model
parameters. This propagates parameter uncertainty
through the model, which is then reflected in the
results, and can be used to describe the likelihood that
a treatment decision is optimal. This is distinct from
the use of Monte Carlo simulation in PLS where the
model parameters are fixed and a random number is
used to determine the path of each individual patient.
This propagates variability, and sometimes heteroge-
neity, into the model results. Enough simulations must
be run to ensure that this variation does not affect
identification of the optimal treatment decision. Thus,
executing PSA within PLS requires a two-level simula-
tion where each set of probabilistic inputs is held con-
stant and the required number of patients is simulated
through the model [14]. This can make PSA an order
of 1,000 or 10,000 more computationally expensive in
a PLS structure as compared with a cohort structure,
and it is sometimes for this reason that PSA is omitted
from models employing PLS.
Alternative methods to conduct PSA exist in the
form of analytical model solutions and emulators. A
closed form solution of expected NB, and possibly the
associated uncertainty, may be tractable. That is, the
analyst could define a closed-form approximation or
simplification that gives the expectation of nonlinear
functions using the model parameters. One such exam-
ple would be the use of a Taylor series expansion [15].
Emulators take the form of nonparametric statistical
models of the outputs of a model, such that those out-
puts can be recalculated with minimal time and com-
putational expense when varying the model inputs
according to the associated uncertainty [14]. Neverthe-
less, there are some limitations associated with the use
of emulators; for example, in the number of uncertain
parameters that may be included. It is not yet known
whether they provide a directly exchangeable alterna-
tive to Monte Carlo simulation. Therefore, the imple-
mentation of PSA through Monte Carlo simulation
can be viewed as current practice.
 
Results of the Review
 
The search results are shown in Figure 1. Although not
required by NICE guidance during this period, PSA
was performed in some technology appraisals. One out
of six (17%) models that used PLS, and 16 out of 24
(67%) cohort models conducted PSA. None of the
eight cohort models that omitted PSA cited computa-
tional expense as the reason, whereas two of the PLS
models did. Nevertheless, justification for omission of
PSA was not present in the majority of cases.
 
Case Studies
 
The review identified six assessment reports submit-
ted to NICE where the estimates of expected costs
and outcomes were based on a model structure using
PLS. Details of the included appraisals are given in
Table 1.
We identified four reasons for choosing a PLS struc-
ture over a cohort framework. These were treatment
switching, sampling from patient characteristics,
dependence on patient history, including previous
events and time-in-state, and uncertainty and variabil-
ity. The following review section provides a more
detailed description of these reasons in the context of
their use in the case studies, and assesses their impli-
cations for model structure.
 
Treatment Switching
 
In some disease areas, patients will be treated with a
sequence of interventions. These may involve different
drugs or different dosages of the same drugs. The deci-
sion regarding whether to move a patient to the next
treatment in a sequence may be based on patient char-
acteristics or patient history and therefore subject to
variability. Nevertheless, for a given set of eligibility
criteria for treatment switching, there will not be
uncertainty around whether a patient proceeds to the
next treatment. In other words, patients may vary in
their characteristics and history, and as a result there
will be variation in the number of patients switching
treatment, but for a given set of characteristics and his-
tory there will not be random variation in the number
of patients switching.
Case study 1 assessed the cost-effectiveness of imat-
inib for gastrointestinal stromal tumors (GIST) [16].
Current guidelines at the time of the assessment rec-
ommended an initial dose of 400 mg daily, with the
option of proceeding to a higher dose in the event of a
poor response or disease progression, and withdrawal
of treatment in the absence of benefit after 8 weeks.
Nevertheless, because of a paucity of data, the best
starting dose of imatinib and best treatment pattern
were highly uncertain.
The model had four health states: progressive dis-
ease, treatment with 400 mg imatinib, treatment with
600 mg imatinib and death. Patients in the imatinib
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treatment group began with 400 mg daily: patients
whose disease progressed could move to 600 mg daily,
or move to the progressive disease state. Patients who
failed treatment with 600 mg imatinib daily moved to
the progressive disease state, from which the only tran-
sitions were to remain in state or die. Patients could die
at any stage in the model. Patients in the control group
(i.e., no imatinib) began the model in the progressive
disease state, and could remain in state or die. The
cycle length was 4 weeks, and the time horizon was
10 years.
For those patients who failed to respond to 400 mg
imatinib, a random number was generated to deter-
mine whether they would be moved to 600 mg, or
straight to the progressive disease state. The probabil-
ity of receiving 600 mg was based on the number of
patients who had responded after crossing over from
400 mg to 600 mg imatinib in a clinical trial [17].
In reality, the decision to move from a dose of
400 mg to 600 mg would not be based on random
chance. Although there may be uncertainty about the
number of patients who would respond to 600 mg
after progressing on 400 mg imatinib, this could not be
identified before the treatment decision being taken.
The treatment strategy in practice would involve mov-
ing all eligible patients onto 600 mg. When response is
 
Figure 1
 
Search results. *Two cost-minimiza-
tion analyses, two considered the cost results
alongside trial results; 
 
†
 
One meta-model of
industry submission, one model type unclear.
PSA, probabilistic sensitivity analysis.
Published appraisals January 2002–January
2005
Included model developed by independent
assessment group
40
Patient-level
simulation
6 (1 PSA)
Cohort
24 (16 PSA)
Cost analysis*
4 (0 PSA)
Other†
2 (0 PSA)
Decision tree
4 (0 PSA)
 
Table 1
 
Examples of the use of patient-level simulation in NICE assessment reports
 
Case 
study Title
Gave justification for
choice of PLS?
Estimate decision
uncertainty?
1 Imatinib for the treatment of patients with unresectable and/or metastatic 
gastrointestinal stromal tumors—a systematic review and economic 
evaluation [18]
Yes No
2 The clinical effectiveness and cost effectiveness of prevention and treatment of 
osteoporosis [20]
Yes Yes
3 The effectiveness of infliximab and etanercept for the treatment of rheumatoid 
arthritis: a systematic review and economic evaluation [22]
Yes No
4 The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid 
arthritis in adults [23]
Yes No
5 The clinical effectiveness and cost-effectiveness of newer drugs for children 
with epilepsy [24]
Yes No
6 Coronary artery stents: rapid systematic review & economic evaluation [29] No No
 
NICE, National Institute for Clinical Excellence; PLS, patient level simulation.
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assessed after 4 weeks, those patients not responding,
as observed in the clinical trial, would then move to the
progressive state. This could be compared with a strat-
egy of not moving patients to a higher dose of the drug
after failure on 400 mg. This alternative approach was
taken by the developers of the GIST model in a sub-
sequent evaluation. This approach enables decisions to
be made about the best treatment pattern, rather than
including current variability in treatment patterns in
the model results. The situation where variability in
patient characteristics may introduce uncertainty into
the number of patients switching treatment is dis-
cussed in the later section on patient histories.
 
Sampling Baseline Patient Characteristics
 
Many characteristics of interest will vary between
patients with the same disease, and some will be
observable at the time at which the treatment decision
is made. In other words, they are observable, able to be
measured with precision, at baseline. If these charac-
teristics determine the likelihood of future events,
parameters in the model will depend on that observa-
tion. It is important to separate the heterogeneous pop-
ulation into homogenous subgroups, and to model
these groups separately; otherwise the results of the
model relate to the average patient, that is, the mean of
the distributions describing the variation of the char-
acteristics of interest. In practice, the treatment deci-
sion can and should be made conditional on the
observed characteristic of each patient, not the
expected characteristic.
Case study 2 considers treatments for osteoporosis
for primary and secondary prevention of fractures
[18]. The model is an update of a previously con-
structed model by the same assessment group [19].
This, in effect, relaxes the time constraint normally
imposed on the development of such models for NICE.
The structure of the model is described as being similar
to  a  Markov  model  with  a  cycle  length  of  1 year,
the difference being that patients are entered into the
model individually, and their history is tracked. The
states in the secondary prevention model are hip frac-
ture, wrist fracture, vertebral fracture, proximal
humerus fracture, breast cancer, coronary heart dis-
ease, and death. The model also tracks the residential
status of each patient to assign costs. The authors state
the belief that reflecting the increased risk of recurrent
fractures after an initial fracture, and tracking the res-
idential status of patients in the model, would be
difficult in a cohort model.
The  secondary  prevention  model  considers  the
cost-effectiveness of treatment strategies for women
presenting at baseline with hip, vertebral, wrist or
proximal humerus fractures. Thus, the PLS is
employed, in part, to track the presenting fracture site
for each woman, because the model assumes a differ-
ent baseline risk of subsequent fractures for each initial
fracture site. Because of the difference in baseline risk
of future events for each initial fracture site, and the
fact that this characteristic is known when the treat-
ment decision is taken, these could have been assessed
as separate subgroups; it is important to be able to
make separate treatment recommendations for each
group. This would considerably reduce the number of
states required to represent that portion of the model
in a cohort framework. This alternative represents a
different characterization of the decision problem
which justifies a simplification of the model structure.
This conditioning on baseline characteristics is distinct
from conditioning on events that occur throughout the
model process, for example, the location of new frac-
ture sites after treatment has been initiated. In this
example, the PLS model structure was also used to
record patient history in the model, and this issue is the
focus of the next section on patient histories.
 
Dependence on Patient Histories
 
Observable variation within groups homogenous in
baseline characteristics may arise as a result of subse-
quent events that occur within the model structure. To
condition model parameters on this observed varia-
tion, it is necessary to record these events in some way.
The method with which to do this will depend on the
choice of model structure.
Case studies 3 and 4 examined treatments for rheu-
matoid arthritis [20,21]. There is a low likelihood of
long-term use for any one disease-modifying antirheu-
matic drug (DMARD), because they are not always
effective, lose effectiveness over time, or cause adverse
effects. Case study 5 assessed the cost-effectiveness of
“newer” antiepileptic drugs (AEDs) in children [22].
Lack of effect on seizure rate and intolerable side
effects means that many patients with epilepsy are
treated with a sequence of drugs. The models com-
pared fixed treatment sequences. The discontinuation
rate of each treatment was modeled as a Weibull dis-
tribution with a shape parameter not equal to one (i.e.,
the  hazard  rate  was  not  constant).  In  other  words,
the probability of discontinuing each treatment was
dependent on the time spent on that treatment. Also,
the availability of future treatment options was
affected by toxic reactions to previous drugs. The PLS
structure allows the analyst to record the realized time
spent receiving each drug for each individual patient.
A separate assessment examined the use of newer
AEDs in adults [23]. The decision problem and the
events to be reflected in the model were very similar to
the model of AEDs in children. As with case studies 3,
4, and 5, time to treatment discontinuation was a func-
tion of time spent on the drug, but this was facilitated
in a cohort model by employing a semi-Markov frame-
work. This semi-Markov model was built in the
statistical programming language R [24], which can
manipulate n-dimensional arrays and track the time
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spent in each state. This alternative model structure
enabled PSA to be undertaken to provide an estimate
of decision uncertainty, without sacrificing the time-
dependent structure of the model.
 
Probabilistic Sensitivity Analysis with PLS
 
As can be seen in Table 1, case study 2 formally
assessed decision uncertainty [18]. This was made fea-
sible through the use of an emulator employing Gaus-
sian processes [14]. The full model was run 80 times
using different values for the inputs to estimate a non-
parametric relationship between the input parameters
and the outputs of the model. This “model of a model”
could then be analyzed relatively quickly to produce
an estimate of decision uncertainty. The use of 80 runs
of the model, as compared with perhaps 10,000 runs
for PSA, considerably reduces the computing power
and time required to estimate decision uncertainty
within a PLS model structure.
 
Discussion
 
If it is accepted that adoption decisions should be made
with consideration of the associated decision uncer-
tainty, then we may say that models submitted to
decision-makers have a dual requirement to estimate
expected NB and characterize decision uncertainty.
The use of PLS is often justified with reference to the
first of these. In other words, the claim is made that it
would not be possible to estimate NB accurately using
a cohort framework for that particular decision prob-
lem. In our review, we have identified four reasons for
choosing PLS, and showed that none of these neces-
sarily preclude the use of a cohort framework. We have
also identified an example where a formal estimate of
decision uncertainty was obtained alongside a compu-
tationally expensive PLS model structure, showing that
the two are not mutually exclusive.
This review indicates that the most common justi-
fications for choosing a PLS are the need to incorpo-
rate time and history dependence in transition
probabilities. In a Markov model, these would be han-
dled using tunnel states, and if the number of states
required is very large, the Markov framework may
become unwieldy and inefficient. An alternative was
illustrated whereby time- and state-dependent transi-
tions were represented in a cohort framework using
semi-Markov processes [25,26]. To employ this
method to track elements of patient history within a
cohort framework, it may be necessary to build the
model in appropriate software. The use of alternative
software can provide flexibility to design an alternative
model structure, and may also reduce analysis time.
This is no panacea, because there will be limits to the
gain in analysis time available with alternative soft-
ware, and improved hardware. For example, in the
updated rheumatoid arthritis case study [21], the use
of Borland Delphi [27] instead of TreeAge DATA 3.5
[28] sped up the analysis. Nevertheless, in this partic-
ular case the gain in analysis time was not enough to
facilitate PSA. Dissemination and training are also
required to allow further use of alternative software,
and this may represent an additional constraint.
Time- and state-dependent transitions are easily
handled within PLS. If the use of Monte Carlo simu-
lation to conduct PSA is too computationally ex-
pensive, the requirement to characterize decision
uncertainty could still be met, as evidenced by the use
of an emulator in one case study [18]. Nevertheless, the
use of emulators is still in development, and there are
currently some limitations, for example, in the number
of uncertain input parameters that can be included.
More research is necessary to validate such models
before it is known whether they are exchangeable with
conducting PSA by means of Monte Carlo simulation.
We have shown that where there is a nonlinear rela-
tionship between a characteristic that varies between
patients and the model output, it is necessary to
account for this variability. This is distinct from the
issue of baseline patient characteristics that confer a
different baseline risk of subsequent events (heteroge-
neity), but refers to variability within homogenous
patient subgroups. Importantly, this does not counter
the need to address decision uncertainty because any
nonlinear model which requires an assessment of var-
iability will also need to assess uncertainty to estimate
expected NB. A PLS can address the issue of variabil-
ity, but this can also be addressed within a cohort
framework by employing a two-level simulation. A
third way to address this issue would be to find a
closed-form approximation to the model which sim-
plifies the analysis greatly. The alternatives identified
here should allow the same level of detail in charac-
terizing the decision problem as is possible with a PLS
framework, but with lower computational expense.
Nevertheless, they do require specialized knowledge to
be able to correctly model that decision problem.
So how generalizable are the results of the review
detailed here? An increasing number of models in the
literature have been developed for—or to influence—a
specific decision-making body at a particular point in
time. Such models are typically developed with similar
constraints as the models for NICE described here.
Some models are developed over a longer-time period,
and perhaps with more generous funding. Usually such
analyses are not concerned with the decision problem
of a particular organization, but have a wider set of
aims and objectives. Nevertheless, even models devel-
oped in this way still face binding resource and time
constraints, not least from the research funder. Fur-
thermore, the purpose of all decision models is ulti-
mately to inform real decisions at some point in time.
Therefore, all analysts will simultaneously have to
tackle the tasks of quantifying decision uncertainty
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while reflecting the complexity of the disease process
and effect of the intervention under time and resource
constraints. Hence, the general issues highlighted by
the NICE case studies are relevant to decision models
developed in different contexts.
In conclusion, if the dual requirement of models to
estimate NB and to characterize decision uncertainty is
accepted, then the failure to fulfill the latter require-
ment will limit its value for decision-making. The
claim that a model has been structured to provide a
more appropriate estimate of expected NB but is too
complex for PSA given the analysts’ constraints would
leave the decision-maker without a key element of
information. There are often alternative modeling
approaches to handle particular characteristics of a
decision problem that can be used to reduce the com-
plexity of the model, or to facilitate the conduct of PSA
within a complex model structure, and both of these
do not reduce the ability of the analyst to estimate NB
correctly. This makes it possible to produce probabil-
istic models to estimate expected NB and characterize
decision uncertainty within the constraints of the deci-
sion-making process.
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Exploring the Research Decision Space:
The Expected Value of Information for
Sequential Research Designs
Susan Griffin, MSc, Nicky J. Welton, PhD, Karl Claxton, PhD
Purpose. To investigate the expected value of partial per-
fect information (EVPPI) and the research decisions it can
address. Methods. Expected value of information (EVI)
analysis assesses the expected gain in net benefit from fur-
ther research. Where the expected value of perfect infor-
mation (EVPI) exceeds the costs of additional research,
EVPPI can be used to identify parameters that contribute
most to the EVPI and parameters with no EVPPI that may
be disregarded as targets for further research. Recently, it
was noted that parameters with low EVPPI for a one-off
research design may be associated with high EVPPI when
considered as part of a sequential design. This article
examines the characteristics and role of conditional and
sequential EVPPI in EVI analysis. Results. The calculation
of EVPPI is demonstrated for single parameters, groups
of parameters, and conditional and sequential EVPPI.
Conditional EVPPI is the value of perfect information
about one parameter, conditional on having obtained per-
fect information about another. Sequential EVPPI is the
value of perfect information for a sequential research
design to investigate first one parameter, then another.
Conditional EVPPI differs from the individual EVPPI for
a single parameter. Sequential EVPPI includes elements
from the joint EVPPI for the parameters and the EVPPI for
the first parameter in sequence. Sequential designs allow
abandonment of research on the second parameter on the
basis of additional information obtained on the first. Con-
clusions. The research decision space addressed by EVI
analyses can be widened by incorporating sequential
EVPPI to assess sequential research designs. Key words:
value of information; uncertainty; decision making. (Med
Decis Making XXXX;XX:xx–xx)
In cost-effectiveness analysis, the expected netbenefits (NBsÞ1 of a set of mutually exclusive
health technologies can be compared, based on
some threshold value for the cost per unit of health
outcome, in order to identify the intervention that
would represent the best use of available resources.
The NBs include the health care resources utilized
by patients receiving the health technologies and
the health outcomes experienced by those patients.
The NB of each alternative will be estimated with
uncertainty. It has been argued that, in the absence
of sunk costs2 or adverse impact on the prospects of
further research,3 the decision of which technology
to adopt can be based on expected NB and that
information about decision uncertainty should in-
form questions about whether further research is
required.4 To this end, expected value of informa-
tion (EVI) analysis can be used to estimate whether
there is an expected gain in NB to be made by
obtaining further information to inform the adoption
decision.58 Throughout this article, the gain in NB
through further research refers to the improvement
in NBs associated with the choice of health technol-
ogy. This article will examine in more detail the
way in which EVI analysis can be used to evaluate
a range of research decisions.
The expected value of perfect information (EVPI)
describes the value of further research that would
eliminate all of the parameter uncertainty in the deci-
sion problem and provides an upper bound on the
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value of additional information. The expected value
of partial perfect information (EVPPI) describes the
value of obtaining additional information on a subset
of parameters, that is, eliminating uncertainty in only
some aspects of the decision problem. It has been
suggested that EVPPI can be used to identify those
parameters that contribute most to the EVPI for the
whole decision problem and that might be worthy of
further research. Additionally it has been suggested
that those parameters or groups of parameters associ-
ated with low or no EVPPI may be disregarded as
potential targets for further research.7,912 It has been
emphasized that the sum of the EVPPI for each
parameter in the model need not sum to the EVPI for
the decision problem as a whole and that combina-
tions of parameters may be associated with positive
EVPPI were they to be investigated jointly even if
individually they all exhibit zero EVPPI.13,14
Most existing EVI analyses1517 in the field of
health care have focused on questions about one-off
research designs that can be used to address the fol-
lowing research questions:
1) Do not conduct further research?
2) Conduct research to inform a single parameter in
isolation?
3) Conduct research to inform a group of parameters
simultaneously?
4) Conduct research to inform all the parameters simul-
taneously, that is, the whole decision problem?
We take each in turn to illustrate how EVI analy-
sis can inform these research decisions. The
research decision space is then expanded to include
sequential designs and to show how EVI analysis
can be used to inform a more complete set of
research decisions commonly faced.
ONE-OFF RESEARCH DESIGNS
Is There Value in Any Further Research?
The value of a decision based on current informa-
tion and the value of acquiring additional informa-
tion are based on the decision maker’s objective
function. Given an objective to maximize health
gains subject to an exogenous budget constraint, the
value of information can be expressed in terms of
net health benefits. These are calculated by convert-
ing costs onto the same scale as health using the
incremental cost-effectiveness ratio (the ratio of the
additional costs to additional health outcomes) of
the health care program(s) that would be displaced
by adopting a new intervention. With current infor-
mation, a decision maker should select the interven-
tion (j) that maximizes expected net benefit. The net
benefit of each intervention can be calculated as
a known function of a set of parameters. Given
a decision problem with 2 uncertain parameters, y1
and y2, the value of a decision based on current
information can be expressed as the following:
max
j
Ey1, y2NB j,y1, y2ð Þ: ð1Þ
With perfect information, the decision maker could
select the intervention that maximizes the net benefit
for particular values of y1 and y2: max
j
NB j,y1, y2ð ).
However, the true values of y1and y2 are unknown, so
the expected value of a decision taken with perfect
information is found by averaging the maximum net
benefit over the joint distribution of y1 and y2:
Ey1, y2 max
j
NB j,y1, y2ð Þ: ð2Þ
The value of a decision made with perfect infor-
mation (equation 2) can then be compared to the
value of the same decision based on current infor-
mation (equation 1) in order to determine the
expected value of perfect information (EVPI):
EVPI =Ey1, y2 max
j
NB j, y1, y2ð Þ max
j
Ey1, y2NB j, y1, y2ð Þ: ð3Þ
Additional information only has value when it
would lead to the adoption of a different interven-
tion than the one that would be selected on the basis
of current information. The information gained from
further research is nonrival and can be used to
inform decisions for current and future patients in
the same population. Therefore, the population EVPI
can be expressed as the per patient EVPI multiplied
by the future population of patients expected to bene-
fit from the information. The future population of
patients expected to benefit will be a function of the
duration of research and the expected time horizon
for the current decision problem.18 Assuming an inci-
dence of I in each period t, an expected time horizon
of T, and discount rate r, the discounted population
expected to benefit from research that reports at time
t can be expressed as the following:
P=
XT
t= t
It
1+ rð Þt: ð4Þ
The expected duration of research is likely to dif-
fer depending on the parameter being investigated
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and the research design (e.g., whether it is a random-
ized trial or an observational cohort study). So we
can express the population to benefit from research
on parameter y1, that is, Py1 , in terms of the time
required for research on that parameter to report, ty1 .
The EVPI represents the upper bound for the value
that could be gained from further research. Where the
population EVPI is positive, it must be compared to
the potential costs of further research (C) in order to
establish whether there may be a positive potential
payoff (P). The costs of research include not only
investigative and organizational costs but also any
opportunity cost to patients included in the research.
For example, if the additional research were to
include randomization between alternative treat-
ments, then a proportion of patients would not
receive the intervention with the maximum expected
net benefit on the basis of current evidence. Also
those included in the research will not be able to ben-
efit from the results; that is, the population that can
benefit is used up in the research itself. For there to
be any potential value to further research, the maxi-
mum achievable value must at least exceed the mini-
mum expected cost of research:
Py1, y2 =EVPI :Py1, y2 min Cy1,Cy2ð Þ: ð5Þ
Equation 5 represents a necessary condition. Where
this first necessary condition is met, we may then go
on to calculate the value of obtaining further informa-
tion for a range of more specific research questions. If
the expected payoff is negative, then investing in fur-
ther research would not represent a good use of
available resources, as any value gained from the addi-
tional information would be outweighed by the cost of
obtaining that information.
Is There Value in Further Research to Inform
a Single Parameter in Isolation?
A study could be designed to gather information
about one specific parameter. With perfect informa-
tion about y1, the decision maker could select treat-
ment j that maximizes the expected net benefit over
the remaining uncertain parameter y2. As the true
values of y1 are unknown, this must then be aver-
aged over the distribution of y1:
Ey1 max
j
Ey2|y1NB j,y1, y2ð Þ: ð6Þ
By comparing the value of a decision made with
perfect information about y1 to the value of a decision
made with current information (equation 1), we can
quantify the expected value of further research to
inform a single parameter in isolation:
EVPPIy1 =Ey1 max
j
Ey2|y1NB j, y1, y2ð Þ
max
j
Ey1, y2NB j, y1, y2ð Þ:
ð7Þ
The EVPPI about each parameter must be multi-
plied by the population of patients who stand to
benefit from the additional information,Py1 , and
compared to the potential costs of research to deter-
mine whether there may be a positive potential pay-
off from that research:
Py1 =EVPPIy1 :Py1−Cy1 : ð8Þ
Is There Value in Further Research to Inform
Groups of Parameters Simultaneously?
Further research could inform more than one
parameter so that the results could reduce the uncer-
tainty in a number of inputs simultaneously. Such
research could take the form of a single study gather-
ing information on a set of parameters or a set of
concurrent studies each investigating a different
parameter. In the case of a 2-parameter model,
obtaining perfect information on both y1 and y2
would eliminate all of the decision uncertainty, and
so in this 2-parameter case, the joint EVPPI for y1
and y2 is equivalent to the EVPI (EVPPIy1, y2 =EVPI ).
In order to establish whether there may be a positive
potential payoff from research to update both para-
meters simultaneously, the joint EVPPI should be
multiplied by the population expected to benefit
and compared to the costs of research:
Py1, y2 =EVPPIy1, y2 :Py1, y2  Cy1, y2 : ð9Þ
This also answers question 4: ‘‘Is there value in
further research to inform the whole decision prob-
lem?’’ But more generally, that question can be
informed by evaluating the following:
Py1,..., yn=EVPPIy1,..., yn:Py1,..., yn  Cy1,..., yn
for the total number (N = 1, . . . ,n)
of uncertain parameters.
ð10Þ
The value of information calculations considered
above concerns the value of perfect information so
they can only provide a necessary condition for
deciding to conduct further research. In practice, the
type of research that can be conducted will provide
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only imperfect sample information. The EVPI calcu-
lations described above can be extended to estimate
the expected value of sample information (EVSI)
based on the possible sample results and posteriors
predicted from sampling the prior distributions of
the parameters and their likelihood.19 The EVPI pro-
vides an upper bound to the EVSI, but where the
EVSI exceeds the expected costs of research, a suffi-
cient condition for conducting further research is
met. All of the equations so far described can be
extended to calculate EVSI instead of EVPI. How-
ever, their implementation poses additional compu-
tation burden, as predicted posteriors for alternative
sample sizes need to be established based on a range
of possible sample results.8,19,20
Summary
EVI analyses are based on an assessment of the
value of a decision based on current evidence
(equation 1) and the value of that same decision
based on additional evidence about all of the input
parameters (equation 2), individual input para-
meters (equation 6), or groups of parameters (in
this example, equivalent to equation 2). These ele-
ments of EVI analysis can be combined to answer
a variety of decisions regarding one-off research
designs, that is, whether there would be value in
conducting any single additional study or set of
concurrent additional studies. If the potential pay-
off from an additional study is expected to be posi-
tive, then investing in further research may
represent a valuable use of current resources. The
single-study or simultaneous study design that
provides the largest potential payoff may be
regarded as the priority for research funding. How-
ever, these types of one-off research designs are
not the only research decisions that are available
to policy makers.
SEQUENTIAL RESEARCH DESIGNS
Decisions about one-off research designs cover
only a portion of the total research decision space.
The research decision space can be expanded to
consider the value of a series of studies, each inves-
tigating a different parameter or group of parameters
in turn. This poses a new question not previously
addressed fully in the literature:
5) Is there value in conducting a sequence of research
to inform a set of parameters?
Brand and Small and Chao and others21,22 have
discussed the value of additional information in
terms of updating decisions in a sequential or itera-
tive expected value decision-making framework
but did not address directly a means to establish
the value of sequential data collection. Recently, it
has been noted that additional information about
one parameter will modify the EVPPI associated
with remaining parameters.23 This would indicate
that the value of a sequential research design to
investigate first y1 then y2 cannot be evaluated sim-
ply on the basis of EVPPIy1 and EVPPIy2. What is
required is an estimate of the value of obtaining
additional information on y1, followed by an esti-
mate of the value of obtaining additional informa-
tion on y2, conditional on having already obtained
additional information on y1.
Conditional EVPPI
If research is conducted to obtain additional
information on y2, this in combination with the
information already collected for y1 provides the
decision maker with perfect information on both
parameters. Thus, the expected net benefits of a deci-
sion taken with perfect information on y2 and y1 are
simply equation 2, regardless of whether this infor-
mation was obtained sequentially or simultaneously.
Again, we must compare this to the expected net ben-
efits of the decision made with current information.
But now, current information includes the informa-
tion already collected on y1. Therefore, the decision
based on current information is based on per-
fect knowledge of y1, and its value is given by equa-
tion 5. Thus, the conditional EVPPI for y2 given
perfect information about y1 can be expressed as the
following:
EVPPIy2|y1 =Ey1, y2 max
j
NB j, y1, y2ð Þ
 Ey1 max
j
Ey2|y1NB j, y1, y2ð Þ:
ð11Þ
This value can be multiplied by the population
expected to benefit from the additional information
and compared to the cost of research to determine
the payoff from additional research on a second
parameter conditional on having already conducted
further research on the first:
Py2|y1 =EVPPIy2|y1 :Py2  Cy2 : ð12Þ
This, however, would not answer the question
regarding the value of a sequential research design
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because it does not incorporate the value or cost of
the information obtained on the first parameter in
sequence.
Sequential EVPPI
The total value of a sequential design can be
obtained by combining the value of the information
gained on the first parameter in the sequence with
the conditional EVPPI for the second parameter
in sequence. The value of a sequence evaluating
first y1 then y2 would be the sum of EVPPIy1 and
EVPPIy2|y1only if the decision to conduct research
about y2 did not depend on the resolution of y1.
However, such an a priori research decision would
negate all the potential advantages of a sequential
research design. In evaluating sequential research,
it is important to allow for a change in research
decision conditional on the new information as it
is collected. So for particular resolutions of y1,
there may be no expected value from obtaining
additional information on y2 (EVPPIy2|y1 ≤Cy2 ), and
further research should not be conducted. In these
circumstances, the sequential research design
allows the decision maker to avoid additional
research on y2 when it is not sufficiently valuable,
that is, issue a ‘stop’ decision. For particular resolu-
tions of y1 where EVPPIy2|y1 > Cy2 , the decision may
be to ‘go’ and conduct research on to y2. The choice
set for the decision maker now includes the inter-
vention (j) and the decision about whether to pro-
ceed with research on to the next parameter in
sequence (r). Maximizing the value of the decision
with perfect information within the brackets in
equation 13 determines whether a ‘stop’ or ‘go’
decision is made to research y2 for each particular
value of y1:
seqEVPPIy1, y2 =Ey1 max Ey2|y1 max
j
NB j, y1, y2ð Þ,

max
j
Ey2|y1NB j, y1, y2ð Þ

max
j
Ey1, y2NB j, y1, y2ð Þ:
ð13Þ
In a sequential design, the cost of research into the
first parameter in the sequence is always incurred.
However, research on the second parameter in the
sequence will only proceed and costs be incurred
if the expected payoff is positive. Therefore, the ex-
pected maximum payoff from a sequential design
that investigates y1 first then y2 (Pseqy1, y2 ) can be
expressed as follows:
Pseqy1, y2 =Ey1 max Ey2|y1 max
j
NB j, y1, y2ð Þ

max
j
Ey2 |y1NB j, y1, y2ð Þ

:Py2 + y1  Cy2 , 0

+ Ey1 max
j
Ey2|y1NB j, y1, y2ð Þ

max
j
Ey1, y2NB j, y1, y2ð Þ

:Py1  Cy1
=Ey1 max Ey2|y1 max
j
NB j, y1, y2ð Þ

max
j
Ey2 |y1NB j, y1, y2ð Þ

:Py2 + y1  Cy2 , 0

+Py1:
ð14Þ
Equation 14 provides an answer to question 5: ‘‘Is
there value in further research to inform a set of
parameters sequentially?’’ It describes the expected
maximum payoff from a sequential design before
any of the parameters have been investigated fur-
ther. Sequential EVPPI is composed of the same ele-
ments (equations 1, 2, and 6) that are used to answer
questions 1 to 4, alongside some assessment of the
costs and duration of research. Therefore, the simu-
lations required to estimate equations 1, 2, and 6 can
also be used to estimate each of the elements of
equations 13 and 14, supposing that the Monte Carlo
simulation is employed. Alternative means to esti-
mate value of information could well reduce the
sampling time required.24
COMPARISONS BETWEEN ALTERNATIVE
RESEARCH DESIGNS
For the 2-parameter decision problem used to
illustrate the EVI calculations, there are only 4 pos-
sible mutually exclusive research decisions (no
research, y1 alone, y2 alone, or y1 and y2) when con-
sidering one-off designs. The research decision
space widens to 6 alternatives when considering the
possible sequential designs (y1 then y2, or y2 then
y1). It would be feasible to enumerate the potential
payoffs for all of these possible one-off and sequen-
tial research designs. The decision maker could then
select a design that would maximize the potential
payoff from further research, including consider-
ation of the option for no further research. However,
as the number of parameters (n) increases, the num-
ber of potential research designs and the research
decision space increases dramatically. For a given
number of parameters, n, the number of one-off
research designs is equal to 2n; the number of
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sequential research designs of any length greater
than 2 and including studies that investigate only
a single parameter is given by the number of permu-
tations
Pn
p= 2
n!
npð Þ!. However, a sequence could include
single studies investigating groups (combinations)
of parameters. The number of unique combinations
that can be formed from a set of parameters n is
given by
Pn1
d= 2
n!
d! ndð Þ!, where d is the number of para-
meters investigated jointly, and for each unique
combination, a new set of sequences is possible of
number
Pnd
p= 2
nd+1ð Þ!
ndp+1ð Þ!. It would not be correct to
determine the number of theoretically possible
sequences based on the number of parameters in
a decision model, as this is arguably not relevant to
research design in practice. In reality, some para-
meters in a decision model will not be amenable to
further investigation, and others will be naturally
grouped. In other words, a research design to inves-
tigate a particular parameter of interest may auto-
matically, or at near zero marginal cost, collect
additional information on a number of related para-
meters, and so we may think of groups of parameters
in terms of research sets. The true n is not the num-
ber of parameters in the decision model but the
number of research sets. Yokota and Thompson17
emphasize that any value of information analysis
requires a definition of the set of available actions
and information collection strategies, and so the
need to define the research sets is not limited to con-
sideration of sequential research designs.
Furthermore, if, when evaluating the benefit of
a sequence beginning y1y2, the payoff from proceed-
ing to the second parameter in sequence is never
positive for any value of y1, there is no need
to investigate any sequence beginning with that
ordered pair, no matter how long. Optimizing over
the whole research decision space may be computa-
tionally impractical, but investigating whether any
sequential design of length 2ð n!n2ð Þ!Þ is worth pursing
may be a valuable addition to the current value of
information calculations.
Comparing per Patient Value of Information
It is less easy to discuss the value of information in
isolation of costs for a sequential design than it is
when considering a one-off design, but it may be of
worth to consider the bounds. The expected value of
information from a sequential design will be at least
as great as the value of information about the first
parameter in the sequence. Furthermore, the value of
information of the sequential design cannot exceed
the value of information for both parameters in com-
bination. When there is no additional value from
investigating the second parameter in sequence, the
sequential design collapses back to the EVPPI for the
first parameter in sequence. Where there is always
additional value from investigating the second para-
meter in sequence, the value of information gathered
from a sequential design will be equal to the value
obtained from a one-off research design investigating
both parameters simultaneously.
Comparing Population Benefit
We may assume the duration of a study investi-
gating a number of parameters simultaneously is
determined by the parameter for which the data
takes longest to collect. We may also assume that
collecting data on parameters concurrently will
take less time than investigating those parameters
sequentially, so ty1, y2 = max ty1 , ty2
 
< ty1 + ty2 . The
information on the first parameter in a sequential
design will be available in the same time as would
be taken to investigate that parameter individually.
However, conditional on that information, the
research into the second parameter may or may not
proceed. Thus, for some resolutions of y1, research
will proceed on y2, the results of which would be
available at time t= ty1 + ty2 . For other resolutions of
y1, no further research would be conducted. Patients
from time ty1benefit from the additional information
on y1 (Py1), and for some resolutions, a smaller
population of patients, Py1+ y2 , benefits from addi-
tional information on y2. In contrast, a design that
evaluated y1 and y2 simultaneously would provide
information on both y1 and y2 at time t= ty1, y2 . The
population of patients expected to benefit from addi-
tional information on y1 is smaller, but the popula-
tion expected to benefit from additional information
on y2 is larger. Potentially, if ty1 is short and ty2is
long, the population benefit from a sequential
research design could exceed the population benefit
from a one-off research design investigating both
parameters simultaneously.
Comparing Costs
The total cost of investigating 2 parameters se-
quentially will in general exceed the cost of investi-
gating them simultaneously. This may in part be
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due to economies realized by running a single trial
to investigate both parameters (e.g., each study may
have some element of fixed cost). However, even in
the absence of any economies from a joint design,
the opportunity costs of the sequential design that
does investigate both parameters will generally
exceed the opportunity costs of the joint design
because the length of time taken to gain the addi-
tional information on both parameters will tend to
be greater for a sequential design, Cy1 +Cy2 > Cy1, y2 .
This suggests that where the payoff from research
into the second parameter in sequence is always
positive (for any resolution of the first parameter),
a sequential design will be dominated by a one-off
research design that investigates both parameters
simultaneously.
However, the value of a sequential design derives
from the ability to avoid the cost of research on the
second parameter in sequence on the basis of addi-
tional information collected on the first parameter in
sequence. This suggests that sequential designs may
be most valuable when the costs of investigating the
second parameter in the sequence are significant
and the benefits of investigating the second parame-
ter in the sequence are sensitive to realizations of
the first parameter. In these circumstances, it will be
more likely that research about the second will be
unnecessary.
If the first parameter is relatively cheap to investi-
gate in terms of cost and research time, then the issue
of whether to proceed to the second parameter could
be addressed with little additional opportunity cost
compared to a concurrent research design and poten-
tially great savings. A parallel can be drawn with
Chao and others’22 value of flexibility, in which the
timing of the ‘second-stage’ decision based on
updated information decreases with the timing of the
information (length of the ‘first stage’). For example,
a lengthy randomized trial to establish the rate of
long-term adverse events from a medical intervention
could be circumvented if it was first established in
a small observational study that the health-related
quality of life impacts of such events were too small
for the true rate to impact on the decision. In contrast,
if the small observational study indicated a large
impact on health-related quality of life for those same
adverse events, then further support would be pro-
vided for investing in the randomized trial.
DISCUSSION
Most previous EVI analyses have focused on
questions about one-off research designs. When
assessing the individual EVPPI for each parameter
in the model, it may be tempting to prioritize fur-
ther studies in order of the size of the potential pay-
offs for each design. In this article, we have
discussed how to calculate the payoff from alterna-
tive sequential research designs that account for
learning from the information gathered on each
parameter in sequence and allow a choice of
whether to proceed with research on the next
parameter in sequence. Widening the research
decision space to incorporate sequential designs is
important because the sequence with the largest
expected potential payoff may imply a different
order of research to that indicated by naı¨vely order-
ing the parameters in terms of the EVPPI. This
additional information to inform the order of
research will however come at the cost of increased
analysis time required to perform the value of infor-
mation analyses; thus, the use of sequential EVPI in
practice will be linked to how time consuming it is
to calculate for each given decision problem.
Sequential EVPPI can be used to identify the
parameter or group of parameters that should be
investigated first because it accounts for the impact
of any additional information on the need for further
research. However, it does not determine the order
of research beyond the first study. Once the results
of the first study or set of studies are available, the
previous EVI calculations become obsolete and
a new set incorporating the additional information
is required. In this example, once additional infor-
mation has been collected for y1, the question of
whether to proceed with research on y2 will be
informed by a new calculation of Py2 .
This article focuses on perfect information to
describe alternative research decisions. Of course,
the value of perfect information represents the maxi-
mum value of further research, and in practice,
actual research will only provide imperfect sample
information. Even so, estimating the maximum pay-
off from further research is computationally feasible
and can provide a useful indication of which
research designs are likely to represent a worthwhile
use of available resources. If the expected cost in
a research proposal exceeds the EVPI, then it will
also exceed the EVSI and it may be disregarded as
a valuable use of scarce resources. Currently, opti-
mizing over all possible research design space on
the basis of the EVSI is generally computationally
expensive and may be prohibitive in many common
circumstances. The computational expense of EVSI
calculations would increase if sequential research
designs were also evaluated. Therefore, using this
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type of EVPI analysis to prioritize the research deci-
sion space within a particular decision problem is of
value and can be used to focus expensive EVSI cal-
culations on those research designs which are likely
to be most valuable.
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SUMMARY
Institutions with the responsibility for making adoption (reimbursement) decisions in health care often lack the
remit to demand or commission further research: adoption decisions are their only policy instrument. The decision
to adopt a technology also inﬂuences the prospects of acquiring further evidence because the incentives to conduct
research are reduced and the ethical basis of further clinical trials maybe undermined. In these circumstances the
decision maker must consider whether the beneﬁts of immediate access to a technology exceeds the value of the
evidence which maybe forgone for future patients. We outline how these expected opportunity losses can be
established from the perspective of a societal decision maker with and without the remit to commission research,
and demonstrate how these considerations change the appropriate decision rules in cost-effectiveness analysis.
Importantly, we identify those circumstances in which the approval of a technology that is expected to be cost-
effective should be withheld, i.e. when an ‘only in research’ recommendation should be made. We demonstrate that
a sufﬁcient condition for immediate adoption of a technology can provide incentives for manufacturers to reduce
the price or provide additional supporting evidence. However, decisions based solely on expected net beneﬁt
provide no such incentives, may undermine the evidence base for future clinical practice and reduce expected net
health beneﬁts for the patient population. Copyright r 2010 John Wiley & Sons, Ltd.
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1. INTRODUCTION
Appropriate social decisions about new health-care technologies require a number of questions to be
addressed: (i) is the new technology expected to be cost-effective based on existing evidence; (ii) is
additional evidence required to support its use; (iii) if so, what type of evidence will be most valuable and
(iv) can the evidence needed be provided once the technology is approved for use? If not, or if it is less
likely or more costly to provide, then the decision maker must consider whether the beneﬁts of immediate
access to a technology exceed the value of the evidence which maybe forgone for future patients.
It has been argued that in the absence of sunk cost or other irreversibilities the decision to adopt a
technology can be based on expected cost-effectiveness. The question of whether further evidence is
required can be regarded as a conceptually separate although simultaneous decision based on the same
principles and analysis (Claxton, 1999). However, there are good reasons to believe that adoption or
reimbursement of a technology may damage the prospects of further research being conducted. We will
show that in these circumstances, adoption or reimbursement becomes the only policy instrument
available and decisions can no longer be based on expected cost-effectiveness. Instead there must be
*Correspondence to: Centre for Health Economics, Alcuin A Block, University of York, Heslington, York, YO10 5DD, UK.
E-mail: scg3@york.ac.uk
Copyright r 2010 John Wiley & Sons, Ltd.
some formal assessment of the opportunity loss of immediate adoption (the value of research which may
be forgone) and failure to do so is a dangerous omission and may lead to the adoption and diffusion of
technologies for which current evidence is insufﬁcient, and undermine the evidence base for future
clinical practice. We outline how these expected opportunity losses can be established from the
perspective of a societal decision maker with and without the remit to commission research and
demonstrate how these considerations change the appropriate decision rules in cost-effectiveness
analysis.
2. IS THE TECHNOLOGY EXPECTED TO BE COST-EFFECTIVE?
If the objective of a health-care system is to maximise health gains from available resources then the
decision to adopt or reimburse an alternative (j) should be based on the costs (Cj), health outcomes (Qj)
and the cost-effectiveness threshold (l). The cost-effectiveness of an alternative j can be expressed in
terms of net health beneﬁt (NBj5QjCj/l) (Phelps and Mushlin, 1991; Stinnett and Mullahy, 1998).
Expected net health beneﬁt (E(NBj)) will be uncertain and a decision must be made before it is known
how the uncertain parameters (y) which determine E(NBj) will resolve. With current information, and in
the absence of irreversibility (Palmer and Smith, 2000) or any costs associated with reversing a decision
(Eckermann and Willan, 2008b), the decision maker can choose the intervention that generates the
maximum expected net beneﬁt:
max
j
EyNBðj; yÞ ð1Þ
Net health beneﬁt per patient can be expressed for the population of current and future patients (It)
over the effective life time of the technology (T) discounted at rate r:
PopulationEðNBjÞ ¼ EyNBðj; yÞ 
XT
t¼1
It
ð11rÞt
; ð2Þ
These expected population net health beneﬁts are illustrated in Figure 11 for a new technology (j) and
current clinical practice (j0). The expected incremental cost-effectiveness ratio (ICER) of the new
technology is £25 000 per QALY so is expected to be cost-effective when lZ£25 000 and
EðNBjÞ  EðNBj0 Þ. The difference in population net health beneﬁt between j
 and j0 represents the
expected beneﬁt of immediate adoption based on existing evidence.
Therefore, a necessary and sufﬁcient condition for adopting the new technology is lZICER or
EðNBjÞ  EðNBj0 Þ. This does not mean, however, that uncertainty is irrelevant or that decisions can be
based on limited and poor quality evidence, because the question of whether additional evidence is
required to support the adoption or reimbursement decision must also be addressed (Claxton, 1999).
3. IS MORE EVIDENCE REQUIRED?
If the uncertainty in costs and effects could be immediately resolved, i.e. with perfect information, the
decision maker could select the alternative that maximises the net beneﬁt for each possible value of
y (maxj NBðj; yÞ). However, the true values of y are unknown, so the expected value of a decision taken
with perfect information is found by averaging the maximum net beneﬁt over the joint distribution of y.
EðNBÞ ¼ Ey max
j
NBðj; yÞ ð3Þ
1The ﬁgures used throughout are intended to be illustrative. All the ﬁgures are based on a published analysis of paclitaxel and
PLDH for the treatment of ovarian cancer. (Main et al., 2006).
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This is the maximum expected net health beneﬁt that can be achieved and can also be expressed for the
population of current and future patients: (Phillips et al., 2008; Eckermann and Willan, 2008a)
PopulationEðNBÞ ¼ Ey max
j
NBðj; yÞ 
XT
t¼1
It
ð11rÞt
ð4Þ
This is also illustrated in Figure 1. Resolving uncertainty by conducting further research improves
expected net health beneﬁts (EðNBÞ  maxj EðNBjÞ) because better decisions can be made which
generate more health outcome from the available resources. Therefore, evidence can be valuable in the
same way as access to a new cost-effective technology. The maximum social value of conducting further
research is the difference between the population values of E(NB) and maxj EðNBjÞ, which is the
expected value of perfect information (EVPI). This provides an upper bound on the value of evidence
since actual research will not resolve all the uncertainty and will not be immediately available.
Nevertheless it does provide a necessary condition: research will only be potentially worthwhile if the
EVPI exceeds the expected costs of research (Cr), expressed in health terms. It should be apparent that
there can be circumstances in which the value of additional evidence exceeds the value of access to a
cost-effective technology, e.g. when £25 000rlr£30 000 in Figure 1. In particular, when l5 ICER and
EðNBjÞ ¼ EðNBj0Þ there is no expected gain in health beneﬁts from adopting the new technology but
the EVPI is positive and reaches a maximum.
Adopting new technologies based on expected cost-effectiveness may be appropriate if the decision of
whether further evidence is needed to support its use is made at the same time and on the same basis.
However, in the current policy environment those institutions with responsibility for making adoption
and reimbursement decisions do not always formally address the question of whether further evidence is
required. Even when they do, they often do not have the remit to prioritise and commission research or
have the powers to require that additional research is conducted by the manufacturers of a technology.
This may not be of concern for reimbursement decisions if the prospects of acquiring information
through research are unaffected by the decision to adopt a technology: decisions can continue to be
based on expected cost-effectiveness. However, this is unlikely to be the case for a number of reasons: (i)
the adoption of a technology removes incentives on the manufacturer to conduct further research; (ii)
the early diffusion of a technology means that future clinical trials are less likely to be supported or
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Figure 1. Decisions based on expected cost-effectiveness.
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regarded as ethical by the clinical community, even when pubic funds are made available for such
research; and (iii) patients are unlikely to enroll in clinical trials once they have unrestricted access to the
new technology.
It has been demonstrated that irreversible aspects of adoption decisions or any costs associated with
subsequently reversing decisions (Eckermann and Willan, 2008b; Palmer and Smith, 2000) ought to be
taken into account in both adoption and research decisions. Below we demonstrate that evidence
forgone due to early adoption may also be an important form of irreversibility that ought to be
accounted for. We demonstrate those circumstances when it may be better to deny the approval of a
technology, which is expected to be cost-effective, even when the costs of reversal are zero, if the value of
evidence forgone exceeds the beneﬁts of early access to the technology.
4. CAN THE EVIDENCE BE PROVIDED?
The sufﬁcient condition for adopting a new technology needs to be extended to account for the value of
information that might be forgone. This requires some assessment of the probability that research will
be conducted (a) and when it might report (t), at which point the decision to adopt or reject the
technology can be revised. Initially we consider the situation in which the new technology is expected to
be cost-effective compared with current practice (EðNBjÞ  EðNBj0Þ)
2 and where the reimbursement
authority does not have the remit to commission research.3
4.1. Expected net beneﬁts of rejection
If approval of j is withheld, patients receive current practice, j0, and the associated lower net beneﬁts of
EðNBj0Þ. If research is not conducted and this decision is not revised over the life time of the technology
(t5 1,y,T), these expected net beneﬁts accrue to the population of current and future patients.
However, if research is conducted and reports at time toT, the decision can be revised and the
maximum that subsequent patients are expected to receive is net beneﬁts of E(NB). If the decision
maker does not control research commissioning then some assessment of the probability that research
will be conducted if the technology is rejected is required (aR). Therefore, the expected net beneﬁt of
rejecting j (BR) can be expressed as:
BR ¼ EðNBj0 Þ  Ptot1ð1 aRÞ  EðNBj0Þ  Pt4t1aR  EðNB
Þ  Pt4t; ð5Þ
where the population before any research reports at t5 t is:
Ptot ¼
Xt
t¼1
It
ð11rÞt
;
and the population following research reports at t5 t is:
Pt4t ¼
XT
t¼t
It
ð11rÞt
2If l4ICER the new technology is not expected to be cost effective and should be rejected, in which case we assume the prospects
for further research are unaffected. However, it is possible that some types of evidence may be more difﬁcult to acquire (e.g. long-
term adverse events) if the technology is rejected. This is discussed in more detail in Section 5.
3The decision maker need only consider the expected beneﬁts of any research, whether commissioned by other public bodies or
conducted by manufacturers within or outside their jurisdiction. However, if they were responsible for both adoption and
research decisions they would need to decide whether to commission research taking account of the costs of conducting research
as well as the value of the evidence it will produce. This is discussed in more detail in Section 6.
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By rejecting a new technology in favour of current practice, the prospects for future research are unaffected4:
the manufacturer of the new technology retains an incentive to conduct research to obtain approval and no
change in clinical practice occurs to damage existing trials or remove the ethical basis for future research.
4.2. Expected net beneﬁts of adoption
If the new technology is approved on the basis of current evidence, patients begin to receive j
immediately with higher net expected beneﬁts of EðNBjÞ. If research is not conducted and this decision
is not revised, these expected net beneﬁts accrue to the population of current and future patients over
the life time of the technology (Ptot1Pt4t). However, if research is conducted and reports at time toT,
the decision can be revised and again the maximum subsequent patients receive would also be E(NB).
Therefore some assessment of the probability that research will be conducted if the technology is
adopted is required (aA). The expected net beneﬁt of adopting j
 (BA) can be expressed as:
BA ¼ EðNBjÞ  Ptot1ð1 aAÞ  EðNBjÞ  Pt4t1aA  EðNBÞ  Pt4t ð6Þ
A sufﬁcient condition to adopt a technology should take account of both the expected beneﬁts of
access to the technology and the opportunity loss of the value of the evidence forgone. This can be
expressed as the difference between (6) and (5):
BA  BR ¼ ½EðNBjÞ  EðNBj0ÞðPtot1ð1 aRÞPt4tÞ  ðaR  aAÞ½EðNB
Þ  EðNBjÞPt4t ð7Þ
If adoption reduces the prospects of further research being conducted (aAoaR), or increases the time
taken for research to report, there will be an opportunity loss of the value of information forgone
(EðNBÞ  EðNBjÞ) for future patients (Pt4t) which may be greater than the expected beneﬁts of
immediate access to the new technology (EðNBjÞ  EðNBj0Þ) for the population of patients before any
research which might be conducted reports (Ptot1ð1 aRÞPt4t). It should be clear that the standard
sufﬁcient condition for adopting a technology based on expected cost effectiveness is a special case, i.e.
if the decision to adopt the technology does not affect the prospects of further research (aA5 aR), then
the new technology should be adopted when lZICER and EðNBjÞ  EðNBj0Þ.
5
If adoption reduces the prospects for further research then observing lZICER is no longer sufﬁcient.
This is illustrated in Figure 2 where aA5 0, aR5 1 and t5 2 based on the same example used in Figure 1.
The expected beneﬁts of adopting the technology are the same (BA ¼ PopulationEðNBjÞ in Figure 1)
since aA5 0 in (6) above. But the expected beneﬁt of rejecting the technology is greater than the Population
EðNBj0 Þ because (5) also includes the higher expected net beneﬁt of E(NB
) available in two years time.
The beneﬁt of rejecting the technology has increased so the sufﬁcient condition is no longer that lZICER
but lZ£39 000. Indeed, adopting this technology when l5 ICER would impose a maximum expected
opportunity loss of 1879 QALYs or £47m. Therefore, the expected beneﬁts of immediate access must not
simply be greater than zero but sufﬁciently great to offset the value of any information that maybe forgone.
4.3. Sufﬁcient conditions for approval
Some assessment of aA, aR and t is required to establish a sufﬁcient condition for approval.
Combinations of a and t can be found for which BA5BR for particular values of l. The bold curve in
Figure 3 represents those combinations of aR and t where BA5BR when l5 £30 000 and aA5 0. This
represents the boundary beyond which the sufﬁcient condition for approval is met, i.e. to the north-east
the new technology meets the sufﬁcient condition and should be approved on the basis of current
4See footnote 1.
5If it is assumed that perfect information will become immediately available following rejection then the technology should always
be rejected. This is what would be implicitly assumed by simply comparing the EVPI to the incremental net beneﬁt without
accounting for the timing and probability of research.
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evidence. As aR approaches 1 and t approaches 0 the technology is increasingly likely to be rejected on
the basis of current evidence.
For example, if future research is not expected to report for some time (e.g. t5 4.5) then the new
technology should be approved even though it may displace research that is almost certain to be
conducted. Similarly, if research is less likely to be conduced (e.g. aR5 0.4) then unless it is expected to
report quickly (e.g. t5 1) the technology should also be approved. However, if there is research which is
likely to be conduced (e.g. aR5 0.8) and is likely to report soon (e.g. t5 2) then it may be better to
withhold approval even though the technology is expected to be cost-effective. Boundaries are also
illustrated for a range of cost-effectiveness thresholds. When l5 ICER5 £25 000 there is no region of
acceptance based on current evidence, i.e. standard decision rules are not a sufﬁcient condition for
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Figure 2. Expected beneﬁts of adoption and rejection.
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0
Time research reports ( )
Pr
o
ba
bi
lit
y 
of
 re
se
ar
ch
 
(
R
)
 = £27.000
 = £25k = ICER
λ = £45.000
 = £30.000
 = £26.000
1 2 3 4 5 6 7 8 9 10
λ
λ
λ
λ
Figure 3. Approval boundary (aA5 0).
S. C. GRIFFIN ET AL.
Copyright r 2010 John Wiley & Sons, Ltd. Health Econ. (2010)
DOI: 10.1002/hec
approval. As l is increased the boundary shifts to the south-west and it is more likely that the
technology will be accepted on the basis of current evidence.
4.4. Price, evidence and approval
If manufacturers believe that decision makers approve technologies solely on the basis of expected cost-
effectiveness, they have no incentive to provide evidence other than that required for licensing. They
also have an incentive to price their technology such that its ICER is just below the cost-effectiveness
threshold. By doing so they can minimise research and development costs and fully capture the surplus
to the health-care system. (Claxton, 2007) In contrast, decision rules that consider the opportunity loss
of adoption do provide incentives for manufacturers to provide more evidence to support the
technology or to reduce price. Indeed manufacturers face a trade-off between price reductions or
investing in evaluative research.
The adoption decision can be altered by reducing uncertainty surrounding cost-effectiveness, even if
this leaves the ICER unchanged. For example, if a trial was expected to report in two years with a
probability of 0.8 then the technology would not meet the sufﬁcient condition for approval: this point is
to the south-west of the original boundary for approval (for l5 £30 000) in Figures 3 and 4. However,
approval could have been gained if the manufacturer had provided additional evidence to support the
technology. If the ICER and therefore BA remains unchanged the cost-effectiveness of the new
technology would be less uncertain so the EVPI per patient (EðNBÞ  EðNBjÞ) will be reduced and BR
would be lower. If the EVPI per patient is reduced from 0.032 to 0.020 QALYs, the boundary for
approval shifts to the south-west (from the dashed line in Figure 4 to the solid line) to the point at which
BA5BR when a5 0.8 and t5 2. The new technology now meets the sufﬁcient condition and the
manufacturer would have gained market access.
Instead of investing in additional research, the manufacturer could reduce the price of the new
technology, reducing the ICER and increasing the expected beneﬁts of adoption. For example, if the total
cost is reduced by 3% the technology appears more cost-effective. The ICER falls to £23 753 and
EðNBjÞ  EðNBj0Þ rises from 0.0321 to 0.040 QALYs so BA increases. In this case decision uncertainty
and EVPI per patient are also reduced from 0.032 to 0.025. The boundary for approval in Figure 4 again
shifts to the south-west. The same technology with the same evidence base but with a lower price meets the
sufﬁcient condition and should be approved on the basis of current evidence.6 In summary, both price and
the level of decision uncertainty can be altered to increase the beneﬁts of immediate adoption (BABR),
which means that the sufﬁcient condition for adoption is met at lower combinations of aR and t.
Decision rules that consider the value of evidence forgone would reduce the number of new
technologies approved compared with decisions based solely on expected net beneﬁt. The decision to
reject technologies with ICERs higher than the threshold would be unaffected,7 but some technologies
with ICERs below the threshold would also be rejected. Technologies more likely to be rejected on these
grounds would be those priced such that the ICER is close to the threshold and those were there is more
uncertainty surrounding cost-effectiveness and where the EVPI is highly relative to the expected
additional net beneﬁts. Such decisions would provide clear incentives to manufacturers to either invest
in sufﬁcient evidence to support the technology or price it in such a way that it appears so cost-effective
that decision uncertainty and EVPI are reduced to acceptable levels. Other things being equal, those
that do invest, thereby reducing the uncertainty surrounding the cost-effectiveness of their product at
launch, will be able to gain approval at higher prices than those that do not, proving rewards for socially
valuable research.
6Reducing price will also reduce the EVPI if uncertainty is associated with whether j* is sufﬁciently more effective to justify the
additional cost. However, if the effectiveness of j* compared with j0 is also uncertain then the effect of price reductions will be
limited and will not continually reduce EVPI, i.e. there will still be positive EVPI even if the new technology was free.
7See footnote 1.
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5. WHAT TYPE OF RESEARCH?
The sufﬁcient conditions for adoption outlined above only consider the value of information for the
decision problem as a whole. However, there are different types of evidence that maybe valuable
requiring different types of research. The expression for BA and BR can be extended to consider the
value of information associated with particular groups of parameters that contribute to net beneﬁt
(Ades et al., 2004). This may be useful in two ways: (i) the value of information associated with
particular parameters can indicate to manufacturers and those responsible for commissioning publicly
funded research, not only if further evidence maybe required, but what type of evidence is needed and,
by implication, the appropriate research design; (ii) it may be that some types of research are more likely
to be displaced by an adoption decision than others. Therefore, setting aside the question of whether the
private or public sector should bear the costs of research, the opportunity loss of adoption will depend,
not only, on the overall EVPI for the decision but whether the EVPI is associated with parameters
which require particular research designs.
For example, if there are two uncertain parameters, y1; y2 [ y, which determine expected net health
beneﬁt in (1), there are three, mutually exclusive research possibilities8: (i) research on y1 only; (ii)
research on y2 only or (iii) as previously, research informing all the uncertainties (y1 and y2 together).
The value of perfect parameter information (EVPPI) per patient can be calculated for each of these
possibilities. For example the value of research on y1 is described by:
EVPPIy1 ¼ Ey1 maxj Ey2NBðj; y1; y2Þ maxj EyNBðj; yÞ; ð8Þ
In this case, since there are only two parameters EVPPIy1;y2 ¼ EðNB
Þ  EðNBjÞ ¼ EVPI.
An assessment of the probability that each of these three types of research will be conducted is
required if the technology is rejected or approved:
aR ¼ a
y1
R1a
y2
R1a
y1; y2
R ; and aA ¼ a
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Figure 4. Price, evidence and approval (l5 £30 000, and aA5 0).
8Sequences of research could also be considered, e.g. research on y1 followed by y2 or y2 followed by y1. The EVPI for such
sequences can be established (Grifﬁn et al., 2009). However, for simplicity but without loss of generality sequential designs are not
explicitly considered here.
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If research is conducted then some assessment of time at which these different types of study may
report will also be required (ty1 ; ty2 ; ty2 ). Now a sufﬁcient condition will depend on the value of the
different types of research which may be forgone and the time at which they may report. The second
term in the expression for BABR in (7), which represents the expected value of information forgone by
adopting the technology, must be expanded to include each of these elements:
ðay1R  a
y1
A ÞEVPPIy1  Pt4t y11ða
y2
R  a
y2
A ÞEVPPIy2  Pt4t y21ða
y1; y2
R  a
y1; y2
A ÞEVPI  Pt4t y1;y2 ð10Þ
For example, if y1 is an estimate of relative effect of j
 then a randomised clinical trial maybe
required to provide more precise and unbiased estimates. Immediate approval may mean that this type
of experimental research would be regarded as unethical or many not be able to recruit patients even if
public funds were available so ay1R4a
y1
A ¼ 0. Alternatively, y2 may be an estimate of quality of life
associated with clinical events and could be informed by an observational study which may be
undertaken whether or not approval is granted, i.e. ay2R ¼ a
y2
A . In these circumstances, even if the overall
EVPI is high, the technology maybe still be approved if most value is associated additional evidence
about y2. Even if EVPPIy14EVPPIy2 , a trial may take some considerable time to report but results from
an observational study could quickly be available (ty14ty2 ) and the technology may still be approved. It
is also possible that some types of evidence maybe more likely to be acquired (or made more quickly
available) once the technology is approved, e.g. evidence of longer-term adverse events may become
more quickly available with wider use of the technology. In these circumstances there will be a trade-off
between the value of those types of evidence gained and those forgone following adoption. In principle
(10) need not necessarily be positive since ayiRoayiA is possible.
6. NECESSARY AND SUFFICIENT CONDITIONS
The characterisation of the sufﬁcient conditions for approval described above has been simpliﬁed to more
easily demonstrate the essential characteristics of the decision problem. However, they suffer from a
number of limitations that, in principle, can be over come by extending the analysis in a number of ways.
6.1. Assessment of a and s
Some assessment of the probability and timing of research if the technology is approved or rejected is
required. However, any assessment of aR, aA and t will be uncertain, particularly for decision makers
without the remit to prioritise and commission research. This uncertainty can be characterised by
assigning prior distributions to aR, aA and t to represent decision makers’ beliefs. The expectation of BR
and BA taken over these distributions can then be established. The uncertainty associated with the
probability of research will not change the expectation of BR or BA because both are multi-linear in aR
and aA. However, the uncertainty associated with its timing will inﬂuence expectation because both BR
and BA are non-linear in t due to the discounting term in (5) and (6).
Also, a and t have been assumed to be independent and t to be independent of whether the
technology is adopted or rejected. However, adoption may delay as well as displace research. Of course,
more complex characterisations of the prospects and timing of research are possible. For example, by
specifying the probability of research reporting in each discreet period (t5 1,y,T), or by using a
continuous distribution of time to event. In both cases the expectation of BR or BA would be inﬂuenced
by uncertainty due to the non-linearity introduced by discounting.
6.2. A necessary condition
The sufﬁcient conditions described above are based on the possibility of forgoing research which would
have resolved all uncertainty and provided perfect information, so the value evidence forgone (second
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term in (7)) is the upper bound on these opportunity losses. Therefore, BABRZ0 can only be a
sufﬁcient but not necessary condition for immediate approval based on current evidence. A necessary
condition would require some assessment of the Expected Value of the (imperfect) Sample Information
(EVSI) that may be forgone (Ades et al., 2004).
This would require some assessment of the expected sample size and design of future research as well
as aR, aA and t. There will be combinations of aR, aA and t where BABRo0 based on perfect
information (the sufﬁcient condition for approval is not met), but would be positive based on sample
information (a necessary condition would be met), i.e. if perfect information was forgone then approval
should be withheld but since only imperfect sample information will be forgone the technology should
be approved on the basis of current evidence. Although the calculation of EVSI over the range of
expected sample sizes and research designs would be computationally expensive in most practical
applications9 it is possible to establish a threshold value of EVSI below which the technology should be
approved on the basis of current evidence for particular value of aR, aA and t.
For example, if aR5 1, aA5 0 and t5 2 the sufﬁcient condition for approval is not met when
l5 £30 000 (see Figure 3). The technology should only be adopted (pass the necessary condition) if the
EVSI per patient from this research was expected to be less than 0.001 QALYs or £286. Since the EVSI
approaches the EVPI as sample size becomes large and the EVPI per patient is 0.033 QALYs or £990, it
seems unlikely that well-designed research with adequate sample size would provide an EVSI lower than
£286. Therefore, the technology fails both the sufﬁcient and necessary conditions (the value expected to
be forgone is too high) and approval should be withheld until the research reports. Alternatively if
research is less likely and will take longer to report (aR5 0.8, aA5 0 and t5 3) approval should be
granted if the EVSI per patient is expected to be less than 0.0285 QALYs or £855. Since this is very close
to the EVPI, even well-conducted research is likely to generate a lower EVSI unless the sample size is
expected to be very large. Therefore, although the technology fails the sufﬁcient condition (see Figure 3)
it may pass the necessary condition and be approved for immediate use based on existing evidence.
6.3. Prioritising and commissioning research
The sufﬁcient and necessary conditions outlined above are relevant to decision making authorities who
do not have the remit or budget to prioritise and commission research. In these circumstances the
authority need only consider the expected beneﬁts of any research (whether commissioned by public
bodies or conducted by manufacturers within or outside the authorities jurisdiction (Eckermann and
Willan, 2009)) based on an assessment of the probability the research will be undertaken and when it is
likely to report. However, if the authority was responsible for both adoption and research decisions they
would be able to decide whether to commission research or not, assess the time at which it will report,
but also take account of the costs of conducting research as well as the value of the evidence it will
produce.
Therefore, the sufﬁcient condition for adoption needs to be amended so that the costs as well as the
beneﬁts of research are taken into account. For example, if research will not be possible following
adoption due to ethical and recruitment considerations (aA5 0) the beneﬁts of approval from (6)
simplify to:
BA ¼ EðNBjÞ  Ptot1EðNBjÞ  Pt4t ð11Þ
The beneﬁts of rejecting the technology, however, now depend on whether the expected
beneﬁts of conducting research (EðNBÞ  Pt4t) exceed the costs (Cr) expressed in terms of
9A parametric approach to EVSI is computationally less demanding, see Raiffa and Schlaiffer 1967 and has been suggested for the
analysis of health technologies, e.g. Claxton 1999 and Willan and Pinto 2005. However, the computational simplicity requires a
comparison of only two alternatives, an assumption that incremental net beneﬁt is normally distributed and that any sample will
provide information on incremental net beneﬁt directly rather than on the parameters of a model commonly used to estimate it.
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health.10 If they do, then additional research maybe worthwhile and could be commissioned, so aR5 1
and (5) becomes:
BR ¼ EðNBj0 Þ  Ptot1EðNB
Þ  Pt4t  Cr ð12Þ
However, if the costs exceed the expected beneﬁts, research would not be worthwhile even if it was
possible to conduct (aR5 0) and the technology should be adopted, i.e. BR becomes EðNBj0 Þ  Ptot1E
ðNBj0 Þ  Pt4t and BA  BR because EðNBjÞ  EðNBj0Þ.
As previously the expected beneﬁts of research in (12) above is the upper bound because
commissioned research will not resolve all uncertainty and provide perfect information. Therefore, the
difference between (11) and (12) still provides only a sufﬁcient condition to approve the technology
when the decision maker is responsible for both adoption and research decisions. As discussed above
these conditions can be extended to include the expected beneﬁts of different types of evidence and the
costs of associated research as well as the EVSI net of the cost of research, i.e. the Expected Net Beneﬁts
of Sampling (ENBS) when considering necessary conditions.
7. DISCUSSION
Decisions to adopt or reimburse a new technology based on expected cost-effectiveness can only be justiﬁed
(in the absence of other sources of irreversibility or costs of reversal) if its approval and widespread use has
no effect on the prospects of acquiring further evidence that maybe needed. However, there are good
reasons to believe that the approval or reimbursement of a technology will damage the prospects of further
research being conducted, particularly when any decision provides widespread and mandatory access to the
technology, as in the case of the National Institute for Health and Clinical Excellence (NICE) in the UK. In
these circumstances the decision to adopt a technology cannot be separated from the question of whether
the evidence to support such a decision is sufﬁcient. The decision maker must consider whether the beneﬁts
of immediate access to a technology exceed the value of the evidence that maybe forgone.
Some informal assessment of these issues may already be implicit in adoption and reimbursement
decisions. For example, NICE makes suggestions for further research when issuing guidance on the use
of technologies and these recommendations are passed to the NHS research and development
programme for consideration. However, it is not clear how the research recommendations are
formulated and they do not have the legal standing to require either the manufacturers to conduct the
research or for it to be prioritised for public funding. NICE also claims to consider the uncertainty
surrounding cost-effectiveness in formulating guidance (NICE, 2004). However, it is not made explicit
how an assessment of decision uncertainty is ‘taken into account’ particularly when assessments of value
of information are often not available. NICE, however, does have the remit to make ‘only in research’
recommendations and has used this in formulating guidance on a number of occasions (Chalkidou
et al., 2007). The question of when an ‘only in research’ recommendation should be made has been
subject to recent debate (Chalmers, 2007; NICE citizens council, 2007).
The circumstances in which the approval of a technology that is expected to be cost-effective should
be withheld, i.e. when an ‘only in research’ recommendation should be made, can be established based
on an explicit and transparent assessment of the value of evidence which may be forgone and the
expected beneﬁts of immediate approval. Such assessments are entirely consistent with estimates of
expected costs-effectiveness, which are already required in many jurisdictions.
Establishing clear decision rules based on an explicit and transparent assessment may have a number
of advantages: First, withholding the approval of a technology which is expected to be cost-effective
10Cr will include the ﬁxed and variable resource costs of the research and any other opportunity costs to those patients enrolled the
study not already captured in (12) and (13), all appropriately discounted and expressed in health terms using l.
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based on current evidence may be difﬁcult to sustain (given the commercial interests of manufacturers
and often the views of the clinical and patient communities) without an explicit and accountable
demonstration of the value of evidence forgone for future patients from immediate adoption. Second,
formal assessment would ensure consistency in decision-making within and between technology
appraisals since estimates of the value of evidence are based on the same analysis used to provide
estimates of the cost-effectiveness of the technologies. And ﬁnally, it is only with explicit decision rules
and transparent assessment that accountable and predictable decisions can be made. Only then will
manufactures face the type of incentives which will encourage the provision of sufﬁcient evidence (of the
right type) to be offered earlier in support of a technology.
The estimates of the opportunity loss of adoption have only considered the value of evidence forgone for
the current decision problem, which only includes existing technologies and the patient population with a
particular indication. This may underestimate opportunity losses in two ways. First, information about
existing technologies will be relevant to the evaluation of new future technologies when they become
available (the existing technology maybe an important comparator and may also contribute to the network
of evidence required to estimate relative effect of a new technology). Second, evidence about a technology
for one indication may well be relevant when considering a future extension of the licensed indication (e.g.
patient group or the sequence and combination of therapy). Forgoing evidence now will clearly impact on
these future decisions. Increasingly adoption and reimbursement decision are being made earlier in the life
cycle of health technologies and closer to licence. At this point, often the only evidence to support the use
are licensing trials and the body of evidence from both publicly funded and sponsored research has not
matured. Therefore, earlier adoption is likely to incur greater opportunity losses and failure to account for
this may have a signiﬁcant impact on the future evidence base for clinical practice.
The possibility of making reimbursement or approval decisions conditional on evidence being
provided (i.e. coverage with evidence development), (Hutton et al., 2007) or negotiating some form of
risk sharing agreement (An OFT market study, 2007; Cooksey, 2006) will need to consider when
additional evidence is needed, the type of evidence required and whether this can or will be gathered
once the technology is approved for use. For example, the type of observational registry data that are
often envisaged will be unable to provide more precise estimates of relative treatment effect because a
comparable control group will not be available. Therefore, setting aside the question of whether
manufacturers or the public sector should bear the costs of research, the opportunity loss of adoption
will depend not only on the overall value of information for the decision, but also on whether the value
is associated types of evidence that will require particular research designs.
Failure to take account of the value of evidence that maybe forgone particularly by early adoption of
technologies is a dangerous omission and may lead to the approval and diffusion of technologies for
which current evidence is insufﬁcient. If reimbursement authorities are not able to commission or
demand that research be conducted then it may be better to deny the approval of a technology which is
expected to be cost-effective and issue an ‘only in research recommendation’. If not, adoption and
reimbursement decisions may undermine the evidence base for future clinical practice and reduce
expected net health beneﬁts for the population of current and future patients.
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Glossary 
ENBS  Expected net benefit of sampling information 
EVPI  Expected value of perfect information 
EVSI  Expected value of sample information 
HRQL  Health related quality of life 
IV  Instrumental variable 
MAR  Missing at random 
MCAR  Missing completely at random 
MNAR  Missing not at random 
PSA  Probabilistic sensitivity analysis 
QALY  Quality adjusted life year 
RCT  Randomised controlled trial 
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